Back to GetFilings.com
1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
------------
FORM 10-K
(MARK ONE)
[X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934
FOR THE FISCAL YEAR ENDED DECEMBER 31, 1995
OR
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
FOR THE TRANSITION PERIOD FROM TO
COMMISSION FILE NUMBER 0-12849
AMERICAN SHARED HOSPITAL SERVICES
(EXACT NAME OF REGISTRANT AS SPECIFIED IN ITS CHARTER)
CALIFORNIA 94-2918118
- ---------------------- ---------------------
STATE OR OTHER JURISDICTION OF (I.R.S EMPLOYER IDENTIFICATION NO.)
INCORPORATION OR ORGANIZATION
FOUR EMBARCADERO CENTER, SUITE 3620, SAN FRANCISCO, CALIFORNIA 94111
- ----------------------------------------------------------------------
(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES) (ZIP CODE)
REGISTRANT'S TELEPHONE NUMBER, INCLUDING AREA CODE (415)788-5300
SECURITIES REGISTERED PURSUANT TO SECTION 12(b) OF THE ACT:
TITLE OF EACH CLASS NAME OF EACH EXCHANGE
------------------- ON WHICH REGISTERED
---------------------
COMMON STOCK NO PAR VALUE AMERICAN STOCK EXCHANGE
PACIFIC STOCK EXCHANGE
SENIOR SUBORDINATED EXCHANGEABLE AMERICAN STOCK EXCHANGE
RESET NOTES DUE 1996
SECURITIES REGISTERED PURSUANT TO SECTION 12(g) OF THE ACT: NONE
INDICATE BY CHECK MARK WHETHER THE REGISTRANT: (1) HAS FILED ALL
REPORTS REQUIRED TO BE FILED BY SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE
ACT OF 1934 DURING THE PRECEDING 12 MONTHS (OR FOR SUCH SHORTER PERIOD THAT THE
REGISTRANT WAS REQUIRED TO FILE SUCH REPORTS), AND (2) HAS BEEN SUBJECT TO SUCH
FILING REQUIREMENTS FOR THE PAST 90 DAYS. YES X NO
--- ---
INDICATE BY CHECK MARK IF DISCLOSURE OF DELINQUENT FILERS PURSUANT TO
ITEM 405 OF REGULATION S-K IS NOT CONTAINED HEREIN, AND WILL NOT BE CONTAINED,
TO THE BEST OF REGISTRANT'S KNOWLEDGE, IN DEFINITIVE PROXY OR INFORMATION
STATEMENTS INCORPORATED BY REFERENCE IN PART III OF THIS FORM 10-K OR ANY
AMENDMENT TO THIS FORM 10-K. [ ]
AS OF MARCH 27, 1996, THE AGGREGATE MARKET VALUE OF THE COMMON STOCK
HELD BY NON-AFFILIATES OF THE REGISTRANT WAS APPROXIMATELY $3,908,068.
NUMBER OF SHARES OF COMMON STOCK OF THE REGISTRANT OUTSTANDING AS OF
MARCH 27, 1996: 4,342,254.
NO DOCUMENTS ARE INCORPORATED BY REFERENCE IN THIS REPORT.
2
PART I
ITEM 1. BUSINESS
GENERAL
American Shared Hospital Services ("ASHS" and together with its
subsidiaries, the "Company") provides shared diagnostic imaging services and
radiotherapy services to approximately 220 hospitals, medical centers and
medical offices located in 22 states. The four principal diagnostic imaging
services provided by the Company are magnetic resonance imaging (MRI), Computed
axial tomography scanning (CT), ultrasound, and nuclear medicine. Radiotherapy
services are performed by the Company through its subsidiary, GK Financing, LLC,
a California limited liability company ("GKF"), which provides Gamma Knives to
two major university medical centers.
ASHS was incorporated in the state of California in September 1983.
ASHS's predecessor, Ernest A. Bates, M.D., LTD. (d/b/a American Shared Hospital
Services), a California limited partnership, was formed in June 1980. In October
1987 the Company acquired Curacare, Inc.("Curacare"), from Tenet Healthcare
Corporation (formerly known as National Medical Enterprises, Inc., "Tenet") for
$22,250,000. The acquisition of Curacare significantly expanded and diversified
the services offered by the Company and increased its market penetration.
Prior to May 1989, the MRI services were provided through AS-C, which
was a joint venture between the Company and MMRI, Inc. ("MMRI"), a California
corporation and a wholly-owned subsidiary of tenet. Effective May 1, 1989, the
Company purchased 100% of MMRI, Inc., ASHS's co-venturer in AS-C, from tenet for
$4,200,000. MMRI's only asset is its 50% interest in AS-C.
In November 1990, the Company started a new wholly-owned subsidiary,
European Shared Medical Services Limited, an English registered company, to
provide MRI services in the United Kingdom. in addition, in August 1993, the
Company incorporated a new wholly-owned subsidiary in California, American
Shared Radiosurgery Services ("ASRS"), to provide Gamma Knife services.
Following its acquisition of Curacare, the Company provided
respiratory therapy services to Acute Care Hospitals. On December 31, 1994, the
Company sold a majority of its respiratory therapy contracts and its respiratory
registry for approximately $4,000,000 in cash plus the assumption by the buyer
of $300,000 in liabilities.
In June 1995, ASHS incorporated two new wholly-owned subsidiaries:
African American Church Health & Economic Services, Inc. ("ACHES"), a California
corporation, and ACHES Insurance Services, Inc., ("AIS"), a California
corporation and insurance agency qualified to sell life, health and disability
insurance in the states of California and New York.
On October 17, 1995, ASHS, through its wholly-owned subsidiary, ASRS,
and Elekta Holdings U.S., Inc. ("Elekta"), through its wholly-owned subsidiary,
GKV
2
3
Investments, Inc., a Georgia corporation ("GKV"), entered into an agreement to
form GKF to provide alternative financing of elekta gamma knife units in the
United States and Brazil. See "Gamma Knife Joint Venture."
OPERATIONS
DIAGNOSTIC IMAGING SERVICES
General. Medical diagnostic imaging systems facilitate the diagnosis
of diseases and disorders at an early stage, often minimizing the amount and
cost of care needed to stabilize, treat or cure the patient and frequently
obviating the need for exploratory surgery. This diagnostic procedure can often
be performed on an out-patient basis eliminating the need for hospitalization.
diagnostic imaging systems utilize energy waves to penetrate human tissue and
generate computer-processed cross-sectional images of the body which can be
displayed either on film or on a video monitor. The Company provides its
diagnostic imaging services to approximately 220 health care providers including
hospitals, clinics and physicians' offices located in 22 states. The Company's
technologists operate the equipment under the direction of licensed physicians
on the customer's staff who order procedures, interpret examination results and
maintain general responsibility for the patient. Generally, the Company directly
charges the hospitals, medical centers and medical offices that have contracted
for its services. The Company, to a significantly lesser extent, bills patients
directly or relies on third party reimbursement.
Third party reimbursement comprises approximately 10% of the Company's
medical services revenues. Non-mri diagnostic imaging services revenues as a
percentage of total medical services revenues were 19%, 21% and 25% in 1995,
1994 and 1993, respectively. Following the sale of a substantial portion of its
respiratory therapy contracts in december 1994 and contract terminations during
1995, the portion of the Company's revenues provided by non-MRI diagnostic
imaging services has declined. See "Management's Discussion and Analysis-Total
Revenues."
The Company provides its diagnostic imaging services on both a shared
and a full- time basis. Shared services are provided based on agreed upon time
periods. The Company contracts with health care providers to provide equipment,
operating technologists, patient care coordinators and, in some cases, operating
supplies.
The major advantages to a health care provider in contracting with the
Company for such services include: (i) Avoiding the high cost of owning and
operating the equipment, (ii) Avoiding the cost of hiring and training technical
personnel and support staff, (iii) Reducing the risks associated with
technological obsolescence or under-utilization of the equipment and services,
and (iv) Not being required to incur the cost of complying with certain
governmental
3
4
Regulations.
Magnetic Resonance Imaging. MRI utilizes magnetic fields and applied
radio waves to obtain computer processed cross-sectional images of the body. MRI
provides clinical images superior to alternative technologies in many
applications by providing information concerning neurologic, orthopedic,
vascular and oncologic diseases. MRI benefits from multiplanar imaging, obviates
the need for ionizing radiation and generally offers superior image resolution
than previously available from CT. The Company is a leading provider of high
field strength MRIS on a shared-service basis. The Company believes that it has
a competitive advantage because of its strategy of operating primarily
top-of-the-line, high magnetic field strength (1.5 tesla superconductive magnet
systems) mobile MRI units. MRI units containing higher strength magnets are
preferred technology because they provide improved image quality, faster
operating speed and greater potential for new applications than do MRI units
with less powerful magnets. Of the Company's 33 MRI units operating at December
31, 1995, 25 of such units are 1.5 tesla units, 4 are 1.0 tesla units, and 4 are
0.5 tesla units. All MRI units are mobile or transportable. The Company had 143
MRI customers at December 31, 1995, compared to 104 customers as of December 31,
1994. MRI revenues constituted 73%, 59% and 52% of total medical services
revenues in years 1995, 1994 and 1993, respectively.
To a greater extent during the past several years, increased
indications of MRI utility plus reductions in equipment costs have allowed more
hospitals to purchase their own system instead of utilizing the Company's
services. This has contributed to a more competitive marketplace for the
Company's services.
Computed Axial Tomography. The Company operates 16 CT units, 15 of
which are housed in specially designed mobile vans serving one or more hospitals
and one of which is a fixed-site unit. CT utilizes multiple x-ray beams and
detectors to derive information which is then synthesized by computers to
produce cross-sectional images of organs or other areas of the body. CT can be
used to perform examinations of any part of the human anatomy and provides a
delineation of tissue not possible with conventional x-ray. CT eliminates the
problem of overlapping structures such as bone and soft tissue inherent in
images produced by conventional x-ray. The most commonly performed CT
examinations are of the brain, abdomen, and lumbo-sacral spine, although
examinations of the chest, pelvis and extremities are also performed. With the
advent of MRI, the relative benefits of ct have decreased. Due to a variety of
factors, including increased competition among manufacturers of CT units, the
selling price of CT units has decreased thereby enabling more hospitals and
health care providers to acquire their own units instead of utilizing the
Company's services. Consequently, the Company has reduced its services in this
area in response to these changes in the market. CT revenues were approximately
10%, 10% and 13% of medical services revenues in 1995, 1994 and 1993,
respectively.
4
5
Ultrasound and Nuclear Medicine. The Company owns and operates
approximately 25 systems providing ultrasound and nuclear medicine services.
Ultrasound technology applies high-frequency pulsed and continuous sound waves
to the body. These sound waves strike vessels and other internal body structures
and echo back to the equipment, where they register upon a video monitor.
Ultrasound systems provide a low medical risk, non-invasive procedure for
determining the primary diagnosis in renal, pancreatic, vascular and abdominal
diseases and obstetrics. Nuclear medicine is a diagnostic imaging system
utilizing short-lived radioactive isotopes and computers to perform various
examinations and process the resulting medical data for the physician to
establish the presence or absence of disease. Nuclear medicine not only provides
an anatomic image but also provides functional information which cannot be
provided by MRI or CT.
Nuclear medicine services of the Company are primarily composed of
Single Photon Emission Computed Tomography ("SPECT") wherein radioisotopes are
injected into the patient and the patient is subsequently imaged by a camera
which moves around the patient. The information received by the camera is then
reconstructed by computer to produce a three dimensional image. Although more
costly, this three dimensional image yields a more accurate image when compared
to other nuclear medicine techniques. The Company provides SPECT services on
both a shared service and full-time basis. Smaller health care providers which
require fewer studies on a regular basis may find it more cost-efficient to
utilize SPECT on a mobile-shared service basis than acquiring their own unit.
Ultrasound and Nuclear Medicine revenues were approximately 8% of medical
services revenues in 1995 and 10% and 12% in 1994 and 1993, respectively.
GAMMA KNIFE
The Company's first Gamma Knife, which is operated at a major
university medical center on a fee-per-procedure basis, commenced operation in
September 1991. The Gamma Knife treats certain vascular malformations and
intracranial tumors without surgery.
In January 1993, the Company entered into a purchase agreement with
the manufacturer for $2,900,000 plus sales tax on its second Gamma Knife and a
fee-for-service lease with a university medical center. During 1993, the
Company advanced $1,090,000 to the equipment manufacturer. Included in this
amount was $800,000 advanced by a third party Lessor and guaranteed by the
Company's chairman and chief executive officer. The Company was unable to fund
the next required advance payment and was notified by the manufacturer that the
Company was in default under the provisions of the purchase agreement.
On April 6, 1994, the Company's agreements to purchase the Gamma Knife
from the manufacturer and lease the Gamma Knife to such university medical
center were formally terminated. Settlement of these agreements entailed the
payment of $130,000 in interest and
5
6
costs to the manufacturer and the university medical center. The Company's
Chairman and Chief Executive Officer simultaneously agreed to enter into
substantially identical purchase and lease obligations as those previously
executed by the Company. On April 6, 1994, new purchase and lease agreements
were entered into by the Company's Chairman and Chief Executive Officer, and the
manufacturer and the university medical center. Of the $1,090,000 in advances
previously paid to the manufacturer, $800,000 was refunded to the third party
lessor and $290,000 (less certain settlement costs) was refunded to the Company
and the Company simultaneously advanced $290,000 to the Chairman and Chief
Executive Officer who executed a promissory note (the "promissory note".)
Concurrently, the third party lessor agreed to fund the remaining $2,610,000
purchase price of the Gamma Knife on behalf of the Chairman and Chief Executive
Officer and the Company received an option to purchase the Gamma Knife. The
option entitled ASHS to purchase the Gamma Knife from its Chairman and Chief
Executive Officer for an amount equal to the remaining debt obligation
associated with the Gamma Knife plus costs and losses, if any, incurred by the
Chairman and Chief Executive Officer. This option was assigned by ASHS to its
subsidiary, GKF, through ASRS and was exercised to purchase the Gamma Knife from
Dr. Bates on February 3, 1996. Upon exercise of the option, the subsidiary also
assumed obligations of the Company relating to the Gamma Knife. Additionally, in
connection with GKF's exercise of the option to acquire the Gamma Knife, the
promissory note was cancelled. The Gamma Knife became operational on August 3,
1994.
GAMMA KNIFE JOINT VENTURE
ASHS, through ASRS, a California corporation, and Elekta, through its
wholly-owned subsidiary, GKV, entered into an operating agreement on October 17,
1995, to form GKF. Pursuant to the operating agreement, as amended, the Company
contributed its Gamma Knife and related assets to GKF in exchange for an 81%
ownership interest held by ASRS in GKF. GKV contributed cash for a 19% ownership
interest in GKF and loaned funds to GKF. GKF will be the preferred alternative
financing provider in the United States and Brazil for the purchase of Gamma
Knife units sold by Elekta Instruments, Inc., a U.S. subsidiary of the Gamma
Knife manufacturer. GKF's primary business will be to provide financing on a
fee-for-service basis. The results of operations of GKF will be included in the
consolidated financial statements of the Company.
CUSTOMERS AND MARKETING
The market for services offered by the Company consists of major urban
medical centers, suburban and rural hospitals, health maintenance organizations
("HMOs") and other managed care providers, governmental institutions, large
multi-specialty medical groups, physician offices and medical clinics. The type
of services offered by the Company in a given area may vary, depending upon such
factors as the size of the client medical care provider,
6
7
the treatment needs of specific patient groups within the client's service area,
the modalities and services required by the client and the number and nature of
competitive services available. The more capital intensive services, such as
MRI, CT, and Gamma Knife, may be effectively offered to urban medical centers,
hospitals, large multi-specialty medical groups, governmental institutions,
larger HMOs and large third-party purchasers of health services. The less
capital intensive services, such as ultrasound, nuclear medicine and, under
certain circumstances, CT, are most effectively offered to suburban and rural
hospitals, physicians' offices and medical clinics. The Company believes that it
offers among the broadest range of services to health care providers of
companies in the shared diagnostic imaging services industry and therefore has a
unique ability to service a broad spectrum of the health care market. The
Company continually monitors developments in the medical equipment industry and
makes an effort to acquire new modalities and equipment as the opportunity
arises in order to maintain its technologically-advanced services and to expand
its market share. When the Company's medical equipment does not generate
adequate revenues, the Company seeks to sell such equipment and to upgrade
existing equipment or acquire newer, more advanced replacement equipment when
appropriate.
During the normal course of business, the Company has customer
contracts which terminate. the Company's sales representatives and operational
managers must replace terminating customers with new customers to maintain the
Company's revenues. Revenue fluctuations may occur dependent upon the maturation
cycle of terminating existing contracts and how quickly replacement customers
can attain the revenue levels of terminating customers. Revenues per customer
are historically higher for established customers. Revenue for all contracts and
contract amendments is recognized as earned based upon services provided for
each monthly period.
The Company employed at the end of 1995 nine sales and marketing as
well as four regional operational managers located in the western, southeastern,
and midwest regions of the country. The Company markets its services through a
direct sales effort emphasizing the quality of its equipment, the reliability
and efficiency of its services, the ability to tailor its services to specific
customer needs and the cost containment benefits realized by the customer when
it utilizes the Company's services. No single customer accounted for 10% or more
of the Company's total revenues in 1994 or 1995.
COMPETITION
Utilization of the Company's diagnostic imaging services depends upon
several factors, including the number of physicians and their respective areas
of practice, the number and nature of competitive diagnostic units available,
and the size and demographics of the service areas. The market for diagnostic
7
8
imaging services is highly competitive. The Company faces competition from other
providers of mobile diagnostic services, some of which may have greater
financial resources than those of the Company, and from equipment manufacturers,
hospitals, imaging centers and health care providers owning in-house diagnostic
units. Significant competitive factors in the diagnostic services market include
equipment price and availability, performance quality, ability to upgrade
equipment performance and software, service and reliability. Adverse market
conditions have significantly impacted providers of mobile services of which
there are only approximately five operating on a national basis. Those with
greater financial resources are better able to withstand adverse market
conditions.
Competition in the MRI service industry has increased since 1992 due
to deterioration of market conditions in that industry. Recent deterioration is
based partly upon a temporary increase in purchases of MRI units by physician
partnerships in the late 1980s and early 1990s, which has largely been halted by
legislation that limits self-referrals. The increased competition among MRI
equipment manufacturers has resulted in greater availability to end users of new
imaging equipment from manufacturers at more competitive pricing than
contracting with full-service providers such as the company.
GOVERNMENT REGULATION
Customers to whom the Company provides services receive payments for
patient care from federal government and private insurer reimbursement
programs. As a result of federal cost-containment legislation currently in
effect, a prospective payment system ("PPS") is utilized to reimburse hospitals
for care given to hospital in-patients covered by federally funded
reimbursement programs. Patients are classified into a diagnosis related group
("DRG") in accordance with the patient's diagnosis, necessary medical
procedures and other factors. Patient reimbursement is limited to a
predetermined amount for each DRG placing material limitations on actual
reimbursement for imaging services. because the reimbursement payment is
predetermined, it does not necessarily cover the cost of all medical services
actually provided. Currently the DRG system is not applicable to out-patient
services, and consequently many health care providers have an incentive to use
contracted shared services on an out-patient basis. In 1986 and again in 1990
the congress enacted legislation requiring the Department of Health and Human
Services ("DHHS") to develop proposals for a PPS for hospital outpatient
services. DHHS has not as yet developed such a proposal, and the effect on the
company's business of such a proposal, if made, cannot be predicted at this
time.
The Company's experience suggests that the hospital in-patient DRG
system and the expansion of managed care has had a favorable impact on the
Company's business. Rising costs in the health care field, together with the
implementation of the DRG system, have encouraged hospitals and other health
care providers to minimize
8
9
costs. The Company's shared diagnostic imaging services allow hospitals and
other medical care providers to provide sophisticated diagnostic equipment and
qualified personnel at a cost directly related to each service rendered to the
patient. In recent years, however, competitive factors (such as equipment
availability and pricing) have limited the Company's ability to benefit from the
favorable impact of drgs and managed care.
Several health care reform proposals have been promulgated during the
Clinton administration. These proposals attempt to increase access to care and
to control rising health care expenditures. Since a specific health care reform
policy has not been enacted, the impact on the Company's business of such a
proposal, if made, cannot be determined at this time.
The payment of remuneration to induce the referral of health care
business has been a subject of increasing governmental and regulatory focus in
recent years. Section 1128b(b) of the Social Security Act (sometimes referred to
as the "federal anti-kickback statute") provides criminal penalties for
individuals or entities that knowingly and willfully offer, pay, solicit or
receive remuneration in order to induce referrals for items or services for
which payment may be made under the Medicare and Medicaid programs and certain
other government funded programs. The Social Security Act provides authority to
the Office of Inspector General through civil proceedings to exclude an
individual or entity from participation in the Medicare and state health
programs if it is determined any such party has violated Section 1128b(b) of the
Social Security Act. The Company believes that it is in compliance with the
federal anti-kickback statute. Additionally, the omnibus Budget Reconciliation
Act of 1993, often referred to as "Stark II" bans physician self referrals to
providers of designated health services with which the physician has a financial
relationship. The term "designated health services" includes: clinical
laboratory services, physical therapy services, occupational therapy services,
radiology or other diagnostic services, radiation therapy services, durable
medical equipment, parenteral and enteral nutrients, equipment and supplies,
home health services, outpatient prescription drugs, inpatient and outpatient
hospital services. On January 1, 1995, the Physician Ownership and Referral Act
of 1993 became effective in California. This legislation prohibits physician
self-referrals for covered goods and services including diagnostic nuclear
medicine and diagnostic imaging if the physician (or the physician's immediate
family) concurrently has a financial interest in the entity receiving the
referral. The Company believes that it is in compliance with the Physician
Ownership and Referral Act of 1993. The Company cannot determine what impact
this legislation will have upon demand for its services.
Legislation in various jurisdictions requires that health facilities
obtain a certificate of need ("con") prior to making expenditures for medical
technology in excess of specified amounts. The con procedure can be expensive
and time consuming, and consequently a health care facility may elect to use the
Company's
9
10
services rather than purchase imaging equipment subject to con requirements. Con
requirements vary from state to state in their application to the operations of
both the Company and its customers. In some jurisdictions the Company is
required to comply with con procedures to provide its services and in other
jurisdictions customers must comply with con procedures before using the
company's services.
The Company's nuclear medicine imaging equipment requires the use of
radioactive isotopes for which there are existing governmental regulations
covering storage, use and disposal. All contracts for nuclear medicine imaging
include arrangements for the disposal of radioactive isotopes either by the
supplier of the isotopes or by agreement with the nuclear medicine department of
the client hospital. The Company is also subject to periodic review concerning
the storage, use and disposal of isotopes used in its nuclear medicine imaging
equipment. The Company has passed all such reviews. The Company's other services
are not generally subject to inspection or review by regulatory bodies.
Mobile diagnostic imaging equipment must, where applicable, comply
with federal and state regulations concerning patient safety, equipment
operating specifications and radiation exposure levels. The equipment
manufacturer is primarily responsible for assuring compliance. The Company
believes that its equipment complies with all such regulations based on the
quality control features and specifications of the equipment manufacturers and
the Company's preventative maintenance program.
Certain states in which the Company operates require that certain of
the Company's personnel be licensed or certified. Such requirements generally
involve educational requirements and the payment of specified fees. All of the
company's technical personnel are duly licensed or certified where required to
perform the services provided by the Company. The Company continually monitors
the compliance of its personnel with such licensing and certification
requirements.
INSURANCE AND INDEMNIFICATION
The Company's contracts with equipment vendors generally do not
contain indemnification provisions. The Company maintains a comprehensive
insurance program covering the value of its property, equipment and vehicles,
subject to deductibles which the Company believes are reasonable.
The Company's customer contracts generally contain mutual
indemnification provisions. The Company maintains general and professional
liability insurance and believes its present insurance coverage and
indemnification agreements are adequate for its business.
10
11
EMPLOYEES
At December 31, 1995, the Company employed approximately 194 employees
on a full-time basis and approximately 135 on a part-time basis. None of these
employees is subject to a collective bargaining agreement and there is no union
representation within the Company. The Company maintains various employee
benefit plans and believes its employee relations are good.
ITEM 2. PROPERTIES
The Company's corporate offices are located at Four Embarcadero
Center, Suite 3620, San Francisco, California, where it leases 2,996 square feet
for $8,122 per month. This lease runs through September 1999.
The Company also leases office and warehouse space in Modesto,
California. An additional property leased by the Company principally for field
operations and sales support is located in West Chicago, Illinois. The Company's
Tennessee office was closed in March 1995.
For the year ended December 31, 1995, the Company's aggregate net
rental expenses for all properties and equipment was approximately $3,458,000.
ITEM 3. LEGAL PROCEEDINGS
There are no material pending legal proceedings involving the Company
or any of its property. The Company knows of no legal or administrative
proceedings against the Company contemplated by governmental authorities.
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
None.
11
12
PART II
ITEM 5. MARKET FOR REGISTRANT'S COMMON EQUITY AND
RELATED STOCKHOLDER MATTERS
The Company's common shares no par value (the "Common Shares") are
currently traded on the American Stock Exchange and The Pacific Stock Exchange.
The announcement by the Company of the terms of a proposed restructuring which
contemplated the exchange of 96% of the Company's subordinated notes for new
Common Shares representing approximately 89.4% of the Company's common equity in
early April 1994 was followed by a significant decline in the market price of
the Common Shares. The Company's losses and net capital deficiency have caused
the Company to no longer satisfy the minimum criteria with respect to net income
and net worth for continued listing published by the AMEX. The per share trading
price is also below the minimum criteria of such exchange. The closing per share
price of the Common Shares was $1.25 at March 27, 1996. The Company has been
advised that its net capital deficiency is inconsistent with the criteria
applied by The PSE for continued listing on such exchange. The AMEX and The PSE
are currently reviewing the Company's financial condition following the
restructuring in order to determine whether the Common Shares will continue to
be listed for trading thereon.
The table below sets forth the high and low closing sales prices of
the Common Shares of ASHS on the American Stock Exchange Consolidated Reporting
System for each full quarter for the last two fiscal years.
PRICES FOR COMMON SHARES
Quarter Ending High Low
- -------------- ---- ---
March 31, 1994 3-1/2 2-3/4
June 30, 1994 13/16 1/2
September 30, 1994 11/16 3/16
December 31, 1994 5/8 3/16
March 31, 1995 5/8 1/4
June 30, 1995 2 5/16
September 30, 1995 2-5/8 1-3/8
December 31, 1995 1-11/16 1-1/4
The Company estimates that there were approximately 1700 beneficial
holders of its Common Shares as of December 31, 1995.
The Company did not pay cash dividends in 1995 and does not intend to
pay dividends in the near future. The Company is prohibited by its credit
agreements from paying dividends on the Common Shares and does not anticipate
being in a position to pay
12
13
dividends for the foreseeable future.
13
14
ITEM 6. SELECTED CONDENSED CONSOLIDATED FINANCIAL DATA
SUMMARY OF OPERATIONS
Year Ended December 31,
--------------------------------------------------------------------------
1995(2) 1994 1993(1) 1992 1991
-------- ---- ------ ---- ----
(AMOUNTS IN THOUSANDS, EXCEPT PER SHARE DATA)
MEDICAL SERVICES REVENUES....................... $34,077 $38,545 $ 39,485 $48,834 $58,952
COSTS OF OPERATIONS............................. 32,675 34,145 37,071 45,169 43,941
SELLING AND ADMINISTRATIVE
EXPENSE.............. 8,432 5,971 6,820 6,273 7,051
INTEREST EXPENSE................................ 5,310 7,423 6,752 7,520 8,542
WRITE-DOWN OF INTANGIBLE ASSETS................. 600 0 5,308 --- ---
------ ------- -------- ------- -------
TOTAL COSTS AND EXPENSES........................ 47,017 47,539 55,951 58,962 59,534
------ ------- -------- ------- -------
(12,940) (8,994) (16,466) (10,128) (582)
GAIN ON SALE OF ASSETS AND EARLY
TERMINATION OF CAPITAL LEASES................. 226 3,294 124 270 138
EQUITY IN EARNINGS (LOSSES) OF PARTNERSHIPS..... 54 85 (51) 51 221
INTEREST AND OTHER INCOME....................... 204 98 742 181 310
-------- ------- -------- ------- --------
(LOSS)/INCOME BEFORE INCOME TAXES AND
EXTRAORDINARY ITEM.............................. (12,456) (5,517) (15,651) (9,626) 87
INCOME TAX PROVISION (BENEFIT).................. 3 20 (7) (111) 63
-------- ------- -------- ------- --------
(LOSS)/INCOME BEFORE EXTRAORDINARY ITEM......... (12,459) (5,537) (15,644) (9,515) 24
EXTRAORDINARY ITEM.............................. 19,803 362 --- --- 1,964
-------- ------- -------- ------- --------
NET INCOME (LOSS)............................... $ 7,344 ($5,175) ($15,644) ($9,515) $ 1,988
======== ======= ======== ======= ========
PRIMARY EARNINGS PER SHARE:
INCOME (LOSS) BEFORE
EXTRAORDINARY ITEM....................... $ (2.96) $ (1.93) $ (5.46) $ (3.39) $ 0.01
EXTRAORDINARY ITEM........................ $ 4.71 $ 0.13 $ 0.00 $ 0.00 $ 0.69
-------- ------- -------- -------- --------
NET INCOME (LOSS)......................... $ 1.75 $ (1.80) $ (5.46) $ (3.39) $0.70
======== ======= ======== ======== ========
FULLY DILUTED EARNINGS PER SHARE:
INCOME (LOSS) BEFORE
EXTRAORDINARY ITEM................... $ (2.96) $ (1.93) $ (5.46) $ (3.39) $ 0.01
EXTRAORDINARY ITEM....................... $ 4.71 $ 0.13 $ 0.00 $ 0.00 $ 0.69
-------- ------ -------- ------- -------
NET INCOME (LOSS)......................... $ 1.75 $ (1.80) $ (5.46) $ (3.39) $ 0.70
======== ======= ======== ======= =======
14
15
December 31,
BALANCE SHEET DATA =========================================================================
1995(2) 1994 1993(1) 1992 1991
-------- ---- ------- ---- ----
(AMOUNTS IN THOUSANDS)
WORKING CAPITAL DEFICIENCY.......................... $ (6,793) $(33,369) $(56,518) $(33,244) $(3,960)
TOTAL ASSETS........................................ 31,345 47,222 50,179 61,440 75,723
CURRENT PORTION OF LONG-TERM DEBT AND
OBLIGATIONS UNDER CAPITALIZED LEASES................ 8,720 11,214 26,635 15,288 10,366
LONG TERM DEBT AND OBLIGATIONS UNDER
CAPITALIZED LEASES LESS CURRENT PORTION............. 26,125 24,244 3,106 19,792 30,950
SENIOR SUBORDINATED NOTES........................... 773 18,467 18,788 18,788 18,788
STOCKHOLDERS' EQUITY (NET CAPITAL
DEFICIENCY)......................................... $(10,576) $(22,341) $(17,754) $ (2,151) $ 7,192
(1) In August 1993, ASHS incorporated a new wholly-owned subsidiary, American
Shared Radiosurgery Services ("ASRS"). Accordingly, the financial data for
the Company presented above include the results of the establishment of
the subsidiary for 1993 through 1995.
(2) In June 1995, ASHS Incorporated a new wholly-owned subsidiary, African
American Church Health and Economic Services, Inc. ("ACHES") and ACHES'
wholly-owned subsidiary, ACHES Insurance Services, Inc. ("AIS"), and in
October 1995, entered into an operating agreement granting ASRS an 81%
ownership interest in GK Financing, LLC. Accordingly, the financial data
for the Company presented above include the results of the establishment
of ACHES, AIS, and GK Financing, LLC for 1995.
15
16
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND
RESULTS OF OPERATIONS
GENERAL
The Company had net income of $7,344,000 ($1.75 per share) on
medical services revenues of $34,077,000 in 1995. The Company had a net loss of
$5,175,000 [($1.80) per share] in 1994 on revenues of $38,545,000.
TOTAL REVENUES
INCREASE INCREASE
(IN THOUSANDS) 1995 (DECREASE) 1994 (DECREASE) 1993
------------ ------- -------- ------- -------- -------
MEDICAL SERVICES $34,077 (11.6%) $38,545 (2.4%) $39,485
Medical services revenues decreased 11.6% in 1995 compared to 1994 and
decreased 2.4% in 1994 compared to 1993. The 11.6% and 2.4% decreases in 1995
and 1994, respectively, were caused primarily by the sale of eight respiratory
therapy contracts and the respiratory registry in December 1994 and a 18%
decrease ($1,398,000) in Respiratory Therapy revenues in 1994.
MRI revenues increased 11% ($2,413,000) in 1995 compared to 1994 and
increased 11% ($2,223,000) in 1994 compared to 1993. The increases in 1995 and
1994 were primarily due to the commencement of new customer contracts and
increased utilization from contracts commenced in prior periods. In addition,
the marketing time required to replace terminating customers lengthened because
of increased competition and the fact that more health care providers already
had access to MRI services. Revenues were also negatively impacted by delays in
the commencement of replacement contracts due to regulatory and site improvement
delays and termination notification periods which certain customers were
obligated to provide to previous providers. MRI revenues as a percentage of
total medical services revenues were 73%, 59% and 52% in years 1995, 1994 and
1993 respectively.
The Company's non-MRI diagnostic imaging services revenues declined
21% ($1,673,000) in 1995 compared to 1994 after a 19% ($1,905,000) decrease in
1994 compared to 1993. The decline in both years was attributable to decreased
CT revenue from the reduction in the CT fleet by two scanners in 1994 and lower
revenue generated on mobile routes, reductions in per-study wholesale prices,
and competition. The Company has had to convert the majority of its CT fleet
from higher revenue and cost mobile routes to lower revenue and cost interim
rental placement units to maintain utilization. Revenues from CT operations
decreased $453,000 in 1995 and $1,170,000 in 1994 from 1993 revenues of
$5,186,000. In addition, nuclear medicine and ultrasound revenues decreased in
1995 compared to 1994 and in 1994 compared to 1993 as a result of the Company's
continued de-emphasis of mobile nuclear and ultrasound contracts and the
expiration of one in-house ultrasound contract in 1994. As a part of its
respiratory therapy contract sale on December 31, 1994, two ultrasound
department contracts were included. These contracts had 1994 revenues of
approximately $850,000. The decrease in nuclear medicine and
16
17
Ultrasound revenues was $1,220,000 in 1995 and $735,000 in 1994 from a 1993
revenue base of $4,736,000. Non-MRI diagnostic imaging services revenues as a
percentage of total medical services revenues was 19%, 21% and 25% for the years
ended 1995, 1994 and 1993 respectively.
COST OF OPERATIONS
Increase Increase
(IN THOUSANDS) 1995 (DECREASE) 1994 (DECREASE) 1993
-------------- ---- ---------- ---- ---------- ----
Cost of Operations,
Exclusive of Write-
Down of Equipment $28,850 (15.5%) $34,145 (6.8%) $36,628
Percentage of Revenue 84.7% 88.6% 92.8%
Write-down of equipment $3,825 NM $ 0 NM $ 443
Percentage of Revenue 11.2% 0.0% 1.1%
The Company's cost of operations, consisting of payroll, maintenance
and supplies, depreciation and amortization, write-down of equipment, equipment
rental and other operating expenses (such as vehicle fuel, building rents,
regional office costs, insurance, property taxes, bad debt expense, fees and
training expenses) decreased $1,470,000 in 1995 and $2,926,000 in 1994 compared
to prior years.
Medical services payroll costs, the largest component of total cost of
operations, decreased by $3,300,000 in 1995 compared to 1994 and by $1,158,000
in 1994 compared to 1993. It has declined as a percent of medical services
revenues (20% in 1995, 27% in 1994 and 29% in 1993) over the past three years
due primarily to the continued decrease in labor intensive (respiratory therapy,
mobile CT and ultrasound) service revenues, the respiratory therapy contract
sale at December 31, 1994, contract expirations and closing of marginally
profitable and unprofitable contracts.
The Company's maintenance and supplies costs were 20%, 20% and 19% of
medical service revenues in 1995, 1994 and 1993 respectively. Maintenance and
supplies costs decreased $1,042,000 in 1995 compared to 1994 and increased
$377,000 in 1994 compared to 1993. The decrease in 1995 is primarily
attributable to pricing reductions on MRI maintenance contracts achieved by the
Company and decreased supply usage associated with the sale and termination of
respiratory therapy contracts. The increase in 1994 was primarily attributable
to equipment aging and additional equipment utilization.
Depreciation and amortization decreased $1,202,000 in 1995 compared to
1994 and increased $1,789,000 in 1994 compared to 1993. The decrease in 1995 is
primarily attributable to the early adoption of Financial Accounting Standards
No. 121 (FAS 121) during the second quarter of 1995 as explained in further
detail below. In addition, the majority of capital leases were extended as of
October 1, 1995 thereby extending the depreciable life of the asset (as leased
assets are depreciated based on leased terms) and decreasing depreciation
expense in the fourth quarter of 1995. The increase in depreciation in 1994 was
primarily due to the impact of the Company's lease restructuring with its
primary equipment lessor. Effective January 1, 1994, equipment leases previously
17
18
accounted for as rentals are accounted for as capitalized leases due to lease
restructuring. Secondarily, depreciation increased due to the full year's impact
of depreciation on capital expenditures related to upgrades performed on certain
MRI units in the last half of 1993.
Equipment rental as a percentage of medical service revenues was 8% in
1995, 4% in 1994 and 13% in 1993. Equipment rental increased $1,228,000 in 1995
compared to 1994 and decreased $3,487,000 in 1994 compared to 1993. The increase
in 1995 is primarily attributable to the commencement of five short term rentals
during 1995. The decrease in equipment rental of $3,487,000 in 1994 compared to
1993 was primarily attributable to the Company's lease restructuring in which
equipment previously accounted for as rentals, effective as of January 1, 1994,
is accounted for as capitalized leases and due to less reliance on interim
equipment rentals.
Other costs of operations as a percentage of medical service revenues
was 12%, 13% and 13% in 1995, 1994 and 1993 respectively. The $979,000 decrease
in 1995 compared to 1994 was primarily attributable to a significant reduction
in regional office administrative costs, property related and bad debt costs.
In connection with the early adoption of FAS 121 during the second
quarter of 1995, management reviewed the recoverability of the carrying value of
long-lived assets, primarily fixed assets, goodwill and deferred costs. The
Company initiated its review of potential loss impairment due to the continuing
changes in the health care environment which have put downward pressure on
customers and equipment and reduced forecasted operating results for certain
assets to a level below previous expectation. Following its review, management
concluded that there was an impairment in the recorded value of fixed assets,
goodwill and deferred costs under FAS 121 based on management's estimate of
future undiscounted cash flows over the estimated remaining useful life of
certain assets. Accordingly, an impairment loss of $4,425,000 was recorded in
the second quarter of 1995 based on the differences between the fair value of
such assets as determined by third parties and the recorded values. The
impairment loss is comprised of a charge for the write-downs of equipment and
deferred assets of $3,825,000 (primarily MRI, CT and nuclear medicine) and
goodwill of $600,000.
SELLING AND ADMINISTRATIVE
INCREASE INCREASE
(IN THOUSANDS) 1995 (DECREASE) 1994 (DECREASE) 1993
------------ ---- ---------- ---- ---------- ----
Selling and
Administrative Costs $8,432 41.2% $5,971 (12.4%) $6,820
Percentage of
Revenue 24.7% 15.5% 17.3%
The Company's selling and administrative costs increased $2,461,000 in
1995 compared to 1994 and decreased $849,000 in 1994 compared to 1993. The
increase in 1995 is primarily attributable to stock compensation expense
totalling $2,679,000 which is comprised of shares and options issued to the
Company's Chairman and Chief Executive Officer, Ernest A. Bates, M.D. Salary and
wage expense was charged $265,000 in the second quarter of 1995 for the issuance
of 184,000 Common Shares to Dr. Bates for his continued service to
18
19
the Company and his personal guarantee of $6,500,000 of indebtedness of the
Company. In addition, during the fourth quarter of 1995, a charge to salary and
wage expense of $2,414,00 was recorded in connection with the grant to Dr.
Bates, following shareholder approval, of an option to acquire 1,495,000
additional Common Shares for $0.01 per share as further consideration for his
continued service to the Company and his personal guarantee of $6,500,000 of the
Company's new credit facilities. See "Liquidity and Capital Resources." The
decrease in 1994 was primarily attributable to a reduction in the costs
associated with the fourth quarter of 1993 write-down of intangible assets
associated with the Company's CuraCare acquisition, reduced travel related
expenses and building rent.
INTEREST EXPENSE
INCREASE INCREASE
(IN THOUSANDS) 1995 (DECREASE) 1994 (DECREASE) 1993
------------ ---- ---------- ---- ---------- ----
Interest Expense $5,310 (28.5%) $7,423 9.9% $6,752
Percentage of
Revenue 15.6% 19.3% 17.1%
The Company's interest expense decreased $2,113,000 in 1995 compared
to 1994 and increased $671,000 in 1994 compared to 1993. The decrease in 1995 is
primarily attributable to the Notes Repurchase (as defined below) on May 17,
1995 and the maturation of existing equipment leases and long-term debt. The
decrease was partially offset by the issuance on May 17, 1995 of Warrants to the
Company's primary equipment lessor, which resulted in a charge to interest
expense of $167,000 (see "Liquidity and Capital Resources"). The increase in
1994 occurred due to the Company's lease restructuring in which equipment
previously accounted for as rentals was treated as capitalized leases effective
January 1, 1994.
WRITE-DOWN OF INTANGIBLE ASSETS
INCREASE INCREASE
(IN THOUSANDS) 1995 (DECREASE) 1994 (DECREASE) 1993
------------ ---- ---------- ---- ---------- ----
Write-down of
Intangible Assets $600 NM $0 NM $5,308
Percentage of Revenue 1.8% 0.0% 13.4%
The Company's write-down of intangible assets increased $600,000 in
1995 as compared to 1994 and decreased $5,308,000 in 1994 as compared to 1993.
The increase in 1995 is solely attributable to the early adoption of FAS 121 in
the second quarter of 1995. See "Cost of Operations" above. The decrease in 1994
is attributable to Company management's evaluation in 1993 of the realizability
of intangible assets associated with its acquisition of CuraCare in 1987.
CuraCare, operates substantially all of the Company's non-MRI businesses,
including CT, Respiratory Therapy, Ultrasound and Nuclear Medicine. Revenues and
operating profits from CuraCare continued to decline significantly over the past
few years despite strategic plans implemented by management. During the fourth
quarter of 1993, Company's management determined it was
19
20
unlikely that the Company's non-MRI businesses would have significant growth
potential in the foreseeable future. Company management, therefore, reduced the
operational management and sales force for its non-MRI businesses.
The changing health care environment and reduced barriers of entry due
to decreased equipment costs for non-MRI businesses contributed to losses in
1993. The Company has determined, based on its methodology of evaluating the
recoverability of intangible assets, that the forecasted cashflow for non-MRI
businesses did not support the future amortization of the intangible asset
balance of $5,867,000 at December 31, 1992, for these modalities.
The Company projected forward its results from operations and
undiscounted cash flows for five years to analyze the recoverability of its
intangible assets. The Company, in formulating the financial forecasts,
considered historical trends, current market conditions and potential new trends
and their impact on revenues.
Based on these forecasts it was determined that the cumulative results
of operations and cash flows for non-MRI businesses were inadequate to recover
any portion of the intangible asset balance associated with CuraCare.
Accordingly, the Company wrote-down the intangible asset balance by $5,308,000
in the fourth quarter of 1993. The Company's remaining intangible asset balance
of $1,375,000 at December 31, 1995 relates primarily to its MRI business.
OTHER INCOME AND EXPENSE
INCREASE INCREASE
(IN THOUSANDS) 1995 (DECREASE) 1994 (DECREASE) 1993
------------ ---- -------- ---- -------- ----
Gain on Sale of Assets
and Early Termination
of Capital Leases $226 (93.1%) 3,294 2,556% $124
Percentage of Revenue 0.7% 8.5% 0.3%
Equity in Earnings
(Losses) of Partnerships 54 (36.5%) 85 267% (51)
Percentage of Revenue 0.2% 0.2% (0.1%)
Interest and Other Income 204 108.2% 98 87% 742
Percentage of Revenue 0.6% 0.3% 1.9%
The Company's gain on sale of assets and early termination of capital
leases decreased $3,068,000 in 1995 compared to 1994 and increased $3,170,000 in
1994 compared to 1993. The gain on sale of assets in 1994 of $3,294,000 was
primarily due to the Respiratory Therapy contracts sale gain of $3,199,000. The
sale resulted in the Company receiving cash of approximately $4,000,000 and the
buyer assuming approximately $300,000 in liabilities. Gain on sale of equipment
fluctuates depending on the timing of asset dispositions. The Company continued
selling non-essential assets during 1994 and 1995.
Equity in earnings (losses) of partnerships decreased $31,000 in 1995
compared to 1994 due primarily to lower equipment
20
21
utilization on the partnership's two CT scanners during 1995. Equity in earnings
(losses) of partnerships increased $136,000 in 1994 compared to 1993 due
primarily to the company's share ($94,000) of a reserve for uncollectible
receivables from a terminated partnership taken in 1993.
Interest and other income increased $106,000 in 1995 compared to 1994.
The largest component of the increase was the settlement of litigation related
to a respiratory therapy contract included in the December 31, 1994 sale.
Interest and other income decreased $644,000 in 1994 compared to 1993 because
during 1993 the Company's insurance carrier paid a business interruption
insurance claim of $575,000 for lost MRI service revenues in the United Kingdom.
NET INCOME (LOSS)
INCREASE INCREASE
(IN THOUSANDS) 1995 (DECREASE) 1994 (DECREASE) 1993
------------ ---- -------- ---- -------- -----
Loss Before Income Taxes
and Extraordinary Item ($12,456) 125.8% ($5,517) (64.7%) ($15,651)
Percentage of Revenue (36.6%) (14.3%) (39.6%)
Loss Per Share ($2.96) 53.4% ($1.93) (64.7%) ($5.46)
Extraordinary item $19,803 5370% $362 NM $ 0
Extraordinary Item,
Per share $4.71 3523% $0.13 NM $ 0
Net Income (Loss) $7,344 242% ($5,175) (66.9%) ($15,644)
Net Income (Loss),
Per Share $1.75 197% ($1.80) (67.0%) ($5.46)
The Company had a loss before income taxes and extraordinary item of
$12,456,000 in 1995 compared to a loss of $5,517,000 for 1994. Included in the
Company's loss for 1995 was a charge of $4,425,000 due to adoption of FAS 121
and stock compensation expense of $2,679,000.
The Company has net income of $7,344,000 for 1995 compared to a loss
of $5,175,000 for 1994. The Company's net income for 1995 included an
extraordinary gain of $19,803,000 from its debt restructuring recorded on May
17, 1995. The gain resulted from the purchase of $17,694,000 aggregate face
amount plus $8,853,000 of accrued and unpaid interest of the Company's 14-3/4%
and 16-1/2% Senior Subordinated Notes due October 15, 1996 (the "Subordinated
Notes"), net of cash, Common Shares and warrants to purchase Common Shares (the
"Warrants") issued, and transaction related costs of $3,893,000, $1,836,000 and
$1,015,000 respectively.
The 1994 net loss was primarily attributable to the reduction in
medical services revenues and interest on the Subordinated Notes. The loss was
partially offset by a gain on the sale of assets.
During September 1994, the Company recognized an extraordinary gain on
the early extinguishment of indebtedness of $362,000. The extraordinary gain
resulted from the repurchase of $321,000 face amount plus $115,000 of accrued
and unpaid interest of the
21
22
Company's 14-3/4% Senior Subordinated Notes net of income tax and deferred
financing costs of $10,000 for $64,000 in cash. The 1993 net loss of $15,644,000
was primarily attributable to the significant reduction in medical services
revenues, the write-down of intangible CuraCare assets and interest on the
Subordinated Notes.
LIQUIDITY AND CAPITAL RESOURCES
The Company had cash and cash equivalents of $452,000 at December 31,
1995 compared to $1,225,000 at December 31, 1994. The Company's cash position
decreased in 1995 because the Company's cash flow was insufficient to meet its
debt and capital lease obligations.
On May 17, 1995, the Company repurchased for cash and securities
approximately 96% of its outstanding Subordinated Notes (the"Notes Repurchase").
The Notes Repurchase, together with the December 1994 Lease Restructuring (as
defined below) and the availability of up to $8,000,000 of new debt financing,
concluded a broad restructuring of the Company's obligations.
In 1992, the Company determined that it would not generate sufficient
revenues or achieve sufficient expense reductions to meet in full its scheduled
debt and lease obligations. Accordingly, the Company suspended interest payments
under the Subordinated Notes beginning with the October 15, 1992 semi-annual
interest payment and suspended lease payments on a significant portion of its
equipment leases from December 1, 1992. As a result, the Company was in default
under substantially all of its debt and lease obligations and the holders had
the right to accelerate such obligations. The Company stated that any such
acceleration would cause it to seek a liquidation in bankruptcy.
The Company engaged in restructuring negotiations with its creditors
following the actions referred to in the immediately preceding paragraph. As a
result of these negotiations, the Company restructured certain of its
outstanding obligations as described below.
1. Secured Credit Facility. The Company's Revolving Credit Facility was repaid
in full and terminated on February 28, 1995 with a portion of the proceeds of
the sale of eight Respiratory Therapy contracts. A new Revolving Credit Facility
(THE "New Revolver") was entered into in May 1995 in connection with the Notes
Repurchase. (See "Liquidity and Capital Resources - Subordinated Notes.")
2. Equipment Leases. On December 30, 1994, the leases covering substantially
all of the Company's medical equipment were modified to extend the lease terms
and to reduce scheduled lease payments (the "Lease Restructuring"). During 1994,
the Company made monthly aggregate payments based on the estimated restructured
lease payments. In addition, certain accrued and unpaid lease and service
payments were converted into promissory notes in favor of General Electric
Company in the principal amounts of approximately $2,000,000 and $500,000,
respectively (the "GE Notes"). As amended, the GE Notes bear interest at an
annual rate of 5% and 10.5%, respectively, payable in arrears, and will mature
in February 2002 and on January 1, 2000, respectively. After November 1995, the
principal balance of the $2 million GE Note amortizes in 75 equal monthly
installments until maturity. The GE Notes are secured by a lien on the accounts
receivable of CuraCare and AS-C
22
23
and a lien on two CT units and one ultrasound unit.
On December 29, 1995 and March 1, 1996, The Company further
restructured certain of its medical equipment leases and the GE Notes to extend
the terms of the leases for periods of up to an additional 26 months, to defer
certain monthly lease payments and to defer certain installment payments on the
GE Notes in the beginning of 1996. This further restructuring results in payment
reductions of approximately $1,200,000 for the Company in 1996.
In connection with the issuance of the GE Notes, the Company issued
warrants to purchase an aggregate of 225,000 Common Shares for $0.01 per share
to General Electric Company, (the "GE Warrants"). Effective March 5, 1996,
97,853 of the GE Warrants were exercised to purchase 97,853 Common Shares.
3. Subordinated Notes. On May 12, 1995, in lieu of a previously negotiated
restructuring that would have resulted in the exchange of approximately 96% of
the Subordinated Notes for new Common Shares that would have represented
approximately 89.4% of the Company's Common Equity, the Company agreed to
repurchase such Subordinated Notes (including accrued and unpaid interest) for a
combination of cash and equity securities equal to approximately 25% of the
Company's fully diluted shares. On May 17, 1995, the Company completed the Notes
Repurchase. After giving effect to certain subsequent adjustments, these holders
received $3,892,681 in cash, plus a total of 1,193,000 Common Shares (equal to
approximately 20% of Ashs's then fully diluted Common Shares), and Warrants for
an additional 314,000 Common Shares (equal to approximately 5% of the then fully
diluted Common Shares). The Warrants are immediately exercisable at $0.75 per
share.
The restructuring results in annual interest savings related to the
Subordinated Notes of approximately $2,890,000. After the restructuring there
remain outstanding approximately $773,000 principal amount of Subordinated Notes
that mature in October 1996 with required annual interest payments of $125,000.
The Company paid accrued and unpaid interest through April 15, 1995, of
approximately $460,000 to holders of Subordinated Notes that were not purchased
on May 17, 1995. The subsequent semi-annual interest payment due October 15,
1995, was paid timely by the Company.
The Notes Repurchase was completed with the proceeds of a new term
loan, the New Revolver and the Gamma Knife Loan (as defined below). The "Term
Loan" is a 48-month level amortizing loan of $2,500,000 at an annual interest
rate of 15%. The Term Loan is secured by various unencumbered equipment and
inventory and certain accounts receivable of AS-C and CuraCare and is guaranteed
by Dr. Bates and Ashs. The proceeds of the Term Loan and New Revolver were used
to repurchase the Subordinated Notes, refinance certain equipment and provide
working capital. As of January 31, 1996, the Lender under the New Revolver was
replaced by an affiliate under substantially identical terms. The New Revolver
is a two year, $4,000,000 interest only Revolving Credit Facility at the Bank of
America Prime Lending Rate plus 5%. The New Revolver is secured by AS-C's and
CuraCare's accounts receivable, certain equipment, inventory and general
intangibles, is guaranteed by Dr. Bates and Ashs, and had a balance of
$3,446,000 as of February 29, 1996. The Company had additional borrowing
capacity under the New Revolver, based on its eligible accounts receivable
valuation, of $554,000 at February 29, 1996. The "Gamma Knife Loan" is an
18-month level amortizing loan of $1,500,000 at an annual interest rate of
10.5%. The proceeds were utilized to refinance the Company's Gamma Knife and
provide additional working capital. The payments on this loan
23
24
were restructured in September 1995 from $90,431 per month to $40,203 per month,
effective September 17, 1995, and to extend the loan term until September 17,
1998.
At the Company's Annual Shareholder Meeting held on October 6, 1995,
the Company's Shareholders approved the issuance of an option for additional
common shares to Dr. Bates as further consideration for his continued service to
the Company and his personal guarantee of $6,500,000 of the Company's new credit
facilities. As a result of this issuance, Dr. Bates held approximately 46% of
the Company's then fully diluted outstanding shares and the Selling
Securityholders received additional Common Shares and Warrants to maintain their
respective fully diluted ownership of the Common Shares.
The various restructuring transactions described above cured all of
the Company's outstanding defaults relating to its debt and lease obligations.
The Company nevertheless remains highly leveraged and has significant cash
payment requirements under its equipment leases and credit facilities. Scheduled
Cash Equipment Capital Lease Payments and Operating Lease Payments during the 12
months ending December 31, 1996 are $8,313,000 and $834,000, respectively, with
related maintenance commitments of approximately $1,847,000. Scheduled interest
and principal payments under the Company's other debt obligations during such
period are approximately $4,824,000. In order to generate sufficient cash to
satisfy these obligations as they become due, the Company's management will do
the following: (i) continue to implement its program of expense reductions; (ii)
identify and sell non-essential assets; (iii) negotiate favorable concessions
from major creditors; (iv) enhance revenues by increasing customer contracts and
equipment utilization; and (v) offer to exchange equity in the Company for
interest bearing debt. There can be no assurance that these measures will
generate sufficient cash to enable the Company to meet its scheduled
obligations. Any inability of the Company to meet its obligations when due would
result in a default which could permit the relevant obligor to accelerate the
obligation and seek other remedies including seizure of the Company's medical
imaging equipment. In such event, the Company would be forced to seek a
liquidation under Chapter 7 or a reorganization under Chapter 11 of the United
States Bankruptcy Code.
IMPACT OF INFLATION AND CHANGING PRICES
The Company does not believe inflation has had a significant impact on
operations, because most of its customer contracts include a cost of living
price adjustment provision, which the Company believes will be sufficient to
offset the impact of any future inflation on the Company's costs of operation.
ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA
See the Index to Consolidated Financial Statements and Financial
Statement Schedules included at page A-1 of this report.
24
25
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND
DISCLOSURE
Not Applicable.
PART III
ITEM 10. DIRECTORS AND EXECUTIVE OFFICERS OF THE REGISTRANT
THE BOARD OF DIRECTORS
The following provides current information concerning those persons who serve
on the Company's Board of Directors.
Ernest A. Bates, M.D. has been a director, the chairman of the Board and
chief executive officer of the Company since it was incorporated in 1983. He
founded the Company's Predecessor Limited Partnership in 1980. Dr. Bates is 59
years old.
Willie R. Barnes has been a director and corporate secretary of the Company
since 1984. He has been a partner in the Law Firm of Musick Peeler & Garrett
since June 1992, was in solo practice from February 1992 until June 1992, was a
partner in the law firm of Katten Muchin Zavis & Weitzman from March 1991 until
January 1992, was a partner in the law firm of Wyman Bautzer Kuchel & Silbert
from April 1989 until its dissolution effective March 14, 1991, and was a
partner in the law firm of Manatt Phelps Rothenberg & Phillips from April 1979
until March 1989. He also is a director of Franchise Finance Corporation of
America. Mr. Barnes is 64 years old.
Matthew Hills became a director of the Company effective February 16, 1996
and has been the chief planning officer for the Berkshire Group, a healthcare
and financial services company, since 1993. From 1990 to 1993, Mr. Hills was a
manager and consultant at the Lek Partnership. Prior to joining Lek, Mr. Hills
was an Associate in the Corporate Finance Department at Drexel Burnham Lambert
from 1987 to 1990. Mr. Hills graduated from Brandeis University in 1981 and from
Harvard Business School in 1987 and is 36 years old. Mr. Hills was nominated to
serve on the Board of Directors by certain shareholders who were participants in
The Notes Repurchase.
John F. Ruffle was elected a director of the Company on May 18, 1995. He
retired in 1993 as Vice-Chairman of the Board of J.P. Morgan & Co. Incorporated
and from the Board of Directors of Morgan Guaranty Trust Co. New York. He also
is a director of Bethlehem Steel Corporation; a director of J.P.M. Advisor
Funds; a director of Trident Corp.; and a Trustee of the Johns Hopkins
University. He is a graduate of the Johns Hopkins University, with an M.B.A. in
Finance from Rutgers University, and is a Certified Public Accountant. Mr.
Ruffle is 59 years old.
Stanley S. Trotman, Jr., became a director of the Company effective February
16, 1996. He has been a managing director with the Health Care Group of
Painewebber, an investment banking firm, since 1995 following the consolidation
of Kidder, Peabody, also an investment banking firm, with Painewebber, and had
previously co-directed Kidder, Peabody's Health Care Group since April 1990.
formerly he had been head of the Health Care Group at Drexel Burnham Lambert,
Inc. where he had been employed for approximately
25
26
22 years. He received his undergraduate degree from Yale University in 1965 and
holds an M.B.A from Columbia Business School in 1967. Mr. Trotman is 52 years
old.
Augustus A. White Iii, M.D. has been a director of the Company since 1990. He
has been a professor of orthopaedic surgery at Harvard Medical School since
1978. He was Orthopaedic Surgeon-In-Chief at Beth Israel Hospital, Boston, MA.,
from 1978 to 1991. He is a director of Orthologic Corporation. Dr. White is 58
years old.
Charles B. Wilson, M.D. has most recently been a director of the Company
since june 1993. He also was a director of the Company from March 1984 until
March 1989. He has been a professor and director of the Brain Tumor Research
Foundation at the University of California Medical Center, San Francisco, since
1968, and from 1968 until April 1, 1994 and March 8, 1996 to present, has held
the position of chief of its Department of Neurosurgery. Dr. Wilson is 66 years
old.
EXECUTIVE OFFICERS
The following table provides current information concerning those persons who
serve as executive officers of the Company. The executive officers were
appointed by the Board of Directors and serve at the discretion of the Board of
Directors.
NAME AGE POSITION
- ----------------------- ----- ------------------------------------------
Ernest A. Bates, M.D. 59 Chairman of the Board of Directors, Chief
Executive Officer and Acting President and
Chief Operating Officer
James A. Gordin 45 Acting Chief Financial Officer
Craig K. Tagawa 42 Senior Vice President
Richard Magary 55 Senior Vice President - Administration,
Assistant Secretary
Gregory Pape 39 Senior Vice President - Sales and Marketing
David Neally 43 Senior Vice President - Operations
- -----------------------
Ernest A. Bates, M.D., founder of the Company, has served in the positions
listed above since the incorporation of the Company, except for the periods May
1, 1991 through November 6, 1992 and February 1989 through August 1989, during
which time Dr. Bates did not serve in the capacity of President and Chief
Operating Officer. Dr. Bates is a graduate of the Johns Hopkins University and
the University of Rochester. He is currently an Assistant Clinical Professor of
Neurosurgery at the University of California Medical Center at San Francisco,
and a member of the Board of Trustees of the Johns Hopkins University and the
University of Rochester.
James A. Gordin has served as vice president and Acting Chief Financial
Officer of the Company since November 1, 1995. From October 1987 through October
1995, he was Vice President-Finance of the Company. From June 1985 through
September 1987, Mr. Gordin was Vice President and Chief Financial Officer of
Curacare, Inc., then a wholly-owned subsidiary of National Medical Enterprises,
Inc. (now Tenet Healthcare Corporation), an owner and operator of
26
27
hospitals and other healthcare businesses. Mr. Gordin joined Curacare, Inc. in
September 1983, as controller. He is a graduate of California State University -
Stanislaus, and is a certified public accountant.
Craig K. Tagawa served as Chief Financial Officer from January 1992 through
October 1995. Previously a Vice President in such capacity, Mr. Tagawa became a
Senior Vice President on February 28, 1993. He is also the Chief Executive
Officer of GK Financing, LLC. from September 1988 through January 1992, Mr.
Tagawa served in various positions with the Company. From 1982 through August
1988, Mr. Tagawa served as Vice President of Finance and Controller of Medical
Ambulatory Care, Inc., the Dialysis Division of National Medical Enterprises,
Inc. (now Tenet Healthcare Corporation), an owner and operator of hospitals and
other health care businesses. Mr. Tagawa received his undergraduate degree from
the University of California at Berkeley and his M.B.A. from Cornell University.
Richard Magary has served as Senior Vice President Administration since
February 28, 1993 and Assistant Secretary since 1985. From April 1987 through
February 1993, Mr. Magary served as a Vice President in the same capacity. From
1982 through March 1987, he served as Chief Financial Officer of the Company and
its predecessor. Mr. Magary is a graduate of the University of San Francisco.
Gregory Pape has served as Senior Vice President - Sales and Marketing since
June 1994. From January 1993 through June 1994, Mr. Pape was a Zone Vice
President - Sales and Marketing for the Company. Mr. Pape served in the capacity
of Regional Sales Manager for the Company for the period from March 1991 through
January 1993. From September 1989 through February 1991, Mr. Pape was a Regional
Sales Manager for Medical Imaging Corporation of America, Inc. Mr. Pape earned
his undergraduate degree at the University of Miami, with postgraduate work in
law at the University of Dayton, Ohio.
David Neally has served as Senior Vice President - Operations since May 1994.
From January 1993 through May 1994, Mr. Neally was a Zone Vice President for
Operations. Prior to January 1993, Mr. Neally had served in a variety of sales
and operations positions since joining Curacare in 1980. Mr. Neally received his
undergraduate degree from John Wood College in Quincy, Illinois and is also a
graduate of St. Mary's School of Cardiopulmonary Technology in Quincy, iIlinois.
COMPLIANCE WITH SECTION 16(A) UNDER THE SECURITIES EXCHANGE ACT OF 1934
Reports filed under the Exchange Act and received by the Company on or
after January 1, 1995, indicate that during 1995 Executive Officers of the
Company did not file timely reports as follows: James R. Brock, David Neally and
Gregory Pape each did not file an initial statement of beneficial ownership of
securities within the required period following such person's appointment as an
executive officer of the Company. Each such person filed the required report in
June 1995. John F. Ruffle did not file an initial statement of beneficial
ownership of securities within the required period following his appointment as
a director of the Company. He filed the required report on June 20, 1995. James
R. Brock did not file a statement of changes of beneficial ownership of
securities for a sale of common shares occurring in September 1995 within the
required period following the transaction. He
27
28
filed the required report on October 16, 1995. Augustus A. White, M.D., did not
file a statement of changes of beneficial ownership of securities for a purchase
of common shares occurring in October 1995 within the required period following
the transaction. The report was filed on March 28, 1996. Ernest A. Bates, M.D.
did not file a statement of changes in beneficial ownership for the 184,000
common shares issued to him in May 1995. He filed the required report on
November 10, 1995 with a statement of beneficial changes of ownership for the
option for 1,495,000 common shares issued to him in October 1995.
ITEM 11. EXECUTIVE COMPENSATION
COMPENSATION OF DIRECTORS
During 1994 and 1995, non-employee directors were scheduled to receive an
annual retainer fee of $5,000 each. The non-employee directors agreed to defer
payment of the retainer fees during 1994 and 1995 to assist the Company with its
cash flow. The 1994 retainer fees were paid in February 1995. The board has
approved the election by any director to receive a portion of his 1995 and 1996
retainer fees in common shares in an amount approximately equalling such fees
otherwise payable in cash. Non-employee directors also are entitled to receive
$1,000 for attendance in person at each regular and special meeting of the board
of directors. In additional, non-employee directors who were members of a
committee of the Board of Directors were entitled to receive $200 for attendance
in person at each committee meeting. Non-employee directors are not entitled to
any fee for Board of Directors or committee meetings held by conference
telephone at which they are not present in person. Of the four board meetings
held during 1995, one was a regular meeting which directors attended in person,
and three were special meetings which were held by conference telephone.
Non-employee directors also received reimbursement of expenses incurred in
attending meetings. No payment is made for attendance at meetings by any
director who is an employee of the Company. The director fee amounts for 1996
will not change from 1994 and 1995 schedules.
COMPENSATION OF EXECUTIVE OFFICERS
The following table sets forth the compensation paid by the Company for
the fiscal years ending December 31, 1993, December 31, 1994 and December 31,
1995 and paid in those years for services rendered in all capacities during
1993, 1994 and 1995, respectively, to the chief executive officer and each
executive officer other than the chief executive officer who served as an
executive officer at December 31, 1995 and earned cash compensation of $100,000
or more during 1995.
28
29
SUMMARY COMPENSATION TABLE
LONG TERM
COMPENSATION
AWARDS(4)
ANNUAL COMPENSATION ------------
SECURITIES
NAME AND PRINCIPAL OTHER ANNUAL UNDERLYING
POSITION YEAR SALARY (3) BONUS COMPENSATION(2) OPTIONS
- -------------------------- ---- ---------- ----- ---------------- ------------
ERNEST A. BATES (3) 1995 $223,253 --- --- 1,495,000
CHAIRMAN OF THE BOARD, 1994 $225,218 --- --- ---
CHIEF EXECUTIVE OFFICER 1993 $235,010 --- --- ---
CRAIG K. TAGAWA (3) 1995 $129,328 $26,003 --- 90,000
SENIOR VICE PRESIDENT 1994 $119,426 --- --- ---
1993 $122,237 --- --- ---
DAVID NEALLY 1995 $ 99,161 $48,076 --- 45,000
SENIOR VICE PRESIDENT 1994 $ 92,827 $17,322 --- ---
OPERATIONS 1993 $ 73,692 $ 5,137 --- 8,250
GREGORY PAPE 1995 $265,745 --- --- 45,000
SENIOR VICE PRESIDENT 1994 $238,186 --- --- ---
SALES AND MARKETING 1993 $196,177 --- --- 20,000
RICHARD MAGARY (3) 1995 $ 99,780 $9,927 --- 45,000
SENIOR VICE PRESIDENT 1994 $ 99,822 --- --- ---
ADMINISTRATION 1993 $104,701 --- --- ---
- --------------------
(1) Each amount under this column includes amounts accrued in 1993, 1994
and 1995 that would have been paid to such persons in such years,
except that such amounts were instead deferred pursuant to the
retirement plan for employees of American Shared Hospital Services and
Curacare, a defined contribution plan and ASHS' flexible benefit plan,
a defined contribution plan. Both plans are available to employees of
the Company generally.
(2) The Company has determined that, with respect to the executive officers
named in the summary compensation table, the aggregate amount of other
benefits does not exceed the lesser of $50,000 or 10% of the total
annual salary and bonus reported in the summary compensation table as
paid to such executive officer in the relevant year.
(3) The lower salary in 1994 compared with 1993 reflects a 5% salary
reduction, effective February 6, 1994.
(4) No restricted stock awards or long-term incentive plan payouts were
made to the executive officers named in the Summary Compensation Table
during the years listed in the Summary Compensation Table.
29
30
OPTION GRANTS IN LAST FISCAL YEAR
The following table sets forth stock options granted in 1995 to each of the
Company's executive officers named in the Summary Compensation Table. The table
also sets forth the hypothetical gains that would exist for the options at the
end of their ten-year terms, assuming compounded rates of stock appreciation of
5% and 10%. The actual future value of the options will depend on the market
value of the Company's common stock.
POTENTIAL REALIZABLE VALUE AT
ASSUMED ANNUAL RATES
OF STOCK PRICE APPRECIATION
INDIVIDUAL GRANTS FOR OPTION TERM(1)
------------------------------------------------------------- ---------------------------------------
PERCENT OF
TOTAL
OPTIONS EXERCISE OR
GRANTED TO BASE PRICE
-----------
EMPLOYEES MARKET
OPTIONS IN FISCAL PRICE ON EXPIRATION
NAME GRANTED YEAR 1995 GRANT DATE DATE 0% 5% 10%
- --------------------- --------- --------- ------------ ---------- ---------- ---------- ---------
ERNEST A. BATES, M.D. 1,495,000 86.4% $0.01/SHARE 8/15/05 $2,414,425 $3,946,800 $6,279,000
-----------
$1.625
CRAIG K. TAGAWA 90,000 5.2% $1.625/SHARE 8/15/05 --- $ 92,250 $ 232,650
------------
(2)
DAVID NEALLY 45,000 2.6% $1.625/SHARE 8/15/05 --- $ 46,125 $ 116,325
------------
(2)
GREGORY PAPE 45,000 2.6% $1.625/SHARE 8/15/05 --- $ 46,125 $ 116,325
------------
(2)
RICHARD MAGARY 45,000 2.6% $1.625/SHARE 8/15/05 --- $ 46,125 $ 116,325
------------
(2)
(1) These amounts, based on assumed annually compounded appreciation rates
of 0%, 5% and 10% as prescribed by Securities and Exchange Commission
rules, are not intended to forecast possible future appreciation, if
any, of the Company's stock price. The Company did not use an
alternative formula for a grant date valuation of the options as it is
not aware of any formula which will determine with reasonable accuracy
a present value based on future unknown or volatile factors.
(2) All such options were granted pursuant to the Company's 1995 stock
option plan and have an exercise price equal to the market price of a
share of the Company's common stock on the AMEX on the respective grant
date.
30
31
LONG-TERM INCENTIVE PLAN AWARDS IN LAST FISCAL YEAR
The "long-term incentive plan awards" ("LTIP awards") table has been
omitted because no LTIP awards made during 1995 to the Company's executive
officers named in the Summary Compensation Table.
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR AND FISCAL YEAR-END OPTION
VALUES
The following table sets forth the number of shares acquired on
exercise of stock options and the aggregate gains realized upon exercise of such
options during 1995, by the Company's executive officers named in the Summary
Compensation Table. The following table also sets forth the number of shares
underlying exercisable and unexercisable options held by such executive officers
on December 31, 1995.
31
32
AGGREGATED OPTION EXERCISES IN LAST FISCAL YEAR
AND FY-END OPTION VALUES
NUMBER OF SECURITIES
UNDERLYING UNEXERCISED VALUE OF UNEXERCISED
OPTIONS IN-THE-MONEY OPTIONS
AT FISCAL YEAR-END AT FISCAL YEAR-END($)
------------------------------ --------------------------------
SHARES
ACQUIRED ON VALUE
NAME EXERCISE REALIZED($) EXERCISABLE UNEXERCISABLE EXERCISABLE UNEXERCISABLE
- -------------------- ----------- ---------- ----------- ------------- ------------ -------------
ERNEST A. BATES, M.D. --- --- 1,495,000 --- $1,947,238(2) ---
CRAIG K. TAGAWA --- --- 125,000 --- (1) ---
DAVID NEALLY --- --- 50,050 4,950 (1) (1)
GREGORY PAPE --- --- 53,000 12,000 (1) (1)
RICHARD MAGARY --- --- 60,000 --- (1) ---
(1) The table does not include the aggregate gains that would have been
realized had those options been exercised on December 31, 1995, because
the option exercise price for each option exceeded the market price per
common share on such date.
(2) This amount is calculated by multiplying the number of common shares
underlying the options at December 31, 1995 by the market price per
common share on such date less the option exercise price.
32
33
STOCK OPTION PLANS
On August 15, 1995, the Board of Directors approved the Company's 1995
stock option plan (the "1995 Plan") providing for non-qualified stock options
and "Incentive Stock Options," subject to approval by the Company's
shareholders. At the 1995 Annual Meeting held on October 6, 1995, the
shareholders approved the 1995 Plan. Under the 1995 plan, 330,000 common shares
have been reserved for awards to officers and other key employees, non-employee
directors and advisors subject to adjustment in the event of a stock split,
stock dividend, recapitalization, reorganization, merger or other similar event
or change in capitalization. Approximately six employees, one advisor, and five
non-employee directors currently participate in the 1995 Plan. Any person
beneficially owning more than 15% of the outstanding common shares will not be
eligible to participate in the 1995 Plan.
The 1995 Plan is administered by the stock option committee of the
Board of Directors (the "Committee") which determines when options become
exercisable, provided that no option shall be exercisable later than ten years
after its date of grant. Options may be exercised during the lifetime of the
optionee only by such optionee and are not transferable other than by optionee's
will or by the laws of descent or distribution or pursuant to beneficiary
designation procedures specified in the 1995 Plan.
Upon shareholder approval, the 1995 Plan became effective as of August
15, 1995, and will terminate ten years thereafter, unless terminated earlier by
the Board of Directors. The Board of Directors may amend the 1995 Plan at any
time except that, without the approval of the shareholders of the Company, no
amendment may, among other things, (i) increase the number of common shares
available under the 1995 Plan, (ii) reduce the minimum purchase price of a
common share subject to an option or (iii) extend the term of the 1995 Plan.
Non-qualified Stock Options. On August 15, 1995, the Committee
granted 243,500 non-qualified options to certain officers of the Company and
other eligible persons, subject to approval of the 1995 Plan by the Company's
shareholders. See "Security Ownership of Certain Beneficial Owners and
Management." Each such option had an initial exercise price of $1.625 per common
share, which was the closing price of the common shares on the AMEX on the date
of grant, and vested immediately. The exercise price of all non-qualified stock
options must be no less than 25% of the fair market value of the common shares
on the date of the grant. Non-qualified options to purchase 4,000 common shares
are also granted automatically to non-employee directors (up to an aggregate of
12,000 options granted to each non-employee director under any plan of the
Company) on the date of each annual meeting of shareholders of the Company and,
on the date a person first becomes a non-employee director, such non-employee
director will be granted a number of options pro-rated for the period of time
until the next annual meeting of shareholders. Such options will be fully
exercisable one year after their date of grant with special provisions for death
and termination for disability and will expire ten years after the date of
grant.
33
34
At its meeting on August 15, 1995, the Committee amended the terms of
substantially all options outstanding under the Company's 1984 Stock Option Plan
(covering an aggregate of approximately 165,000 common shares) to reduce the
initial exercise price to $1.625 per common share, which was the closing price
of common shares on the AMEX on such date.
In the event of certain change of control events or the approval by
shareholders of a reorganization, merger or consolidation (unless the Company's
shareholders receive 60% or more of the stock of the surviving company) or the
approval by shareholders of a liquidation, dissolution or sale of all or
substantially all of the Company's assets, all awards will become fully vested
and be "cashed-out" by the Company except, in the case of a merger or similar
transaction in which the shareholders receive publicly traded common stock, all
outstanding options will become exercisable in full, and each option will
represent a right to acquire the appropriate number of shares of common stock
received in the merger or similar transaction. Special provisions regarding
exercise exist in the event of death or termination for disability.
Incentive Stock Options. No incentive stock option will be
exercisable more than ten years after its date of grant, unless the recipient of
the incentive stock option owns greater than ten percent of the voting power of
all shares of capital stock of the Company (a "ten percent holder"), in which
case the option must be exercised within five years after its date of grant. The
option exercise price of an incentive stock option will not be less than the
fair market value of the common shares on the date of grant of such option,
unless the recipient of the incentive stock option is a ten percent holder, in
which case the option exercise price will be 110% of fair market value. Special
provisions regarding exercise exist in the event of death or termination for
disability.
1995 STOCK OPTION PLAN TABLE
The following table sets forth (i) the number of common shares
underlying options that were granted to the chairman and chief executive officer
and each executive officer named in the summary compensation table under the
1995 Plan, all executive officers as a group and to all persons (other than
non-employee directors and executive officers) eligible to receive awards under
the 1995 Plan and the value of such common shares at August 15, 1995, and (ii)
the number of common shares underlying options granted to non-employee
directors at the 1995 Annual Meeting on October 6, 1995.
34
35
NUMBER OF
COMMON SHARES DOLLAR
UNDERLYING VALUE(S) (5)
NAME AND POSITION OPTIONS ($)
----------------- ------------- -----------
Ernest A. Bates, M.D....................... 0 $0
Chief Executive Officer
Craig K. T Gawa............................ 90,000 (1) 146,250
Senior Vice President
David Neally............................... 45,000 (1) 73,125
Senior Vice President -
Operations
Gregory Pape............................... 45,000 (1) 73,125
Senior Vice President -
Sales and Marketing
Richard Magary............................. 45,000 (1) 73,125
Senior Vice President-
Administration
Executive Group............................ 225,000 (2) 365,625
Non-Executive Officer Group................ 18,500 (3) 30,063
Non-Executive Director Group...............
(3 persons) 12,000 (4) $19,500
(1) Represents options granted on August 15, 1995, subject to Shareholder
approval of the 1995 Plan, at an exercise price equal to $1.625, which
was the closing price of the Common Shares on the AMEX on such date.
(2) Comprises four individuals who were granted options on August 15, 1995,
subject to Shareholder approval of the 1995 Plan, at an exercise price
equal to $1.625, which was the closing price of the Common Shares on
the AMEX on such date.
(3) Comprises three individuals who were granted options on August 15,
1995, subject to Shareholder approval of the 1995 Plan, at an exercise
price equal to $1.625, which was the closing price of the Common Shares
on the AMEX on such date.
(4) The option exercise price per share would be the closing sale price of
the Common Shares on the AMEX on the date of grant. Each option will be
fully exercisable one year after the date of grant and will expire ten
years after the date of grant.
(5) Dollar value of options granted is calculated as the number of Common
Shares underlying the options multiplied by the closing sale price of
the Common Shares on the AMEX on the date of the grant. The taxable
benefit received by each grantee upon exercise of the options will
consist of any increase in the
35
36
price of the Common Shares on the AMEX on the date of exercise
from the closing price on the date of grant.
In addition, the Board of Directors and the Company's shareholders
have approved the terms of a Non-Qualified Stock Option Agreement between the
Company and Dr. Bates. Pursuant to this Agreement, Dr. Bates may purchase, at
any time prior to August 15, 2005, up to 1,495,000 Common Shares at an initial
exercise price of $0.01 per share.
EMPLOYMENT AGREEMENTS
The Company had no employment contracts with its Directors or
Executive Officers named in the Summary Compensation Table in 1995.
ITEM 12. SECURITY OWNERSHIP OF CERTAIN
BENEFICIAL OWNERS AND MANAGEMENT
The following table sets forth certain information regarding the
beneficial ownership of the Company's Common Shares as of March 5, 1996, of (i)
each person known to the Company to own beneficially 5% or more of the Common
Shares, (ii) each Director of the Company, (iii) the Chief Executive Officer and
each other Executive Officer named in the Summary Compensation Table, and (iv)
all Directors and Executive Officers as a group.
36
37
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
COMMON SHARES OWNED BENEFICIALLY
----------------------------------------
AMOUNT AND NATURE OF
NAME AND ADDRESS OF BENEFICIAL BENEFICIAL OWNERSHIP PERCENT OF CLASS
OWNER (5) (10)
- ------------------------------ -------------------- ----------------
Total Number of Shares 6,662,101(6) 100.0%
Ernest A. Bates, M.D. (1) 2,666,000(7) 45.7%
SunAmerica Inc.(2) 128,066(2) 2.9%
SunAmerica Life Insurance 277,473(2) 6.3%
Company(2)
Anchor National Life 406,819 9.2%
Insurance
Company(2)
Lion Advisors, L.P. 384,195(8) 8.7%
1301 Avenue of the
Americas
New York, NY 10019
AIF II, L.P. 170,752(8) 3.9%
c/o Apollo Advisors, L.P.
1999 Avenue of the Stars
Los Angeles, CA 90071
General Electric Company 225,000(9) 5.0%
c/o GE Medical Systems
20825 Swenson Drive
Waukesha, WI 53186
Willie R. Barnes (1) 3,000(7) *
Matthew Hills(1)(3) -- --
John F. Ruffle (1)(4) 21,200 *
Stanley S. Trotman, Jr. -- --
(1)(3)
Augustus A. White, III, M.D. 15,000(7) *
(1)
Charles B. Wilson, M.D. (1) 4,800(7) *
Craig K. Tagawa (1) 127,600(7) 2.9%
Senior Vice President
David Neally (1) 52,800(7) 1.2%
Senior Vice President-
Operations
Richard Magary (1) 73,300(7) 1.7%
Senior Vice President-
Administration
Gregory Pape (1) 57,500(7) 1.3%
Senior Vice President-
Sales and Marketing
All Directors & Executive 3,054,300(7) 49.4%
Officers as a
Group (12 persons)
- --------------
* LESS THAN 1%
(1) The address of each such individual is c/o American Shared Hospital
Services, Four Embarcadero Center, Suite 3620, San Francisco,
California 94111-4155.
37
38
(2) Based on information contained in the Schedule 13d dated May 17, 1995,
as amended November 13, 1995, and March 11, 1996 and filed with the
Securities and Exchange Commission by SunAmerica Inc. and its direct
and indirect subsidiaries, SunAmerica Life Insurance Company (formerly
known as Sun Life Insurance Company of America) and Anchor National
Life Insurance Company, such entities then owned beneficially 557,923
common shares, including immediately exercisable warrants to acquire
116,436 common shares. As of October 6, 1995, such entities were issued
an additional 201,607 common shares and 52,828 warrants. The address of
each beneficial owner is c/o SunAmerica, Inc., 1 SunAmerica Center, Los
Angeles, CA 90067.
(3) Mr. Hills and Mr. Trotman were elected to the Board of Directors
effective February 16, 1996.
(4) Mr. Ruffle was elected to the Board of Directors effective May 18,
1995.
(5) Each person directly or indirectly has sole voting and investment power
with respect to the shares listed under this column as being owned by
such person.
(6) Represents the aggregate of issued and outstanding common shares plus
common shares that all persons or groups of persons are entitled to
acquire upon the exercise of options or warrants within 60 days after
March 5, 1996.
(7) Includes shares underlying options that are currently exercisable or
which will become exercisable within 60 days following March 5, 1996:
Dr. Bates, 1,495,000; Mr. Barnes, 2,000 shares; Dr. White, 12,000
shares; Dr. Wilson, 4,800 shares; Mr. Tagawa, 125,000 shares; Mr.
Neally, 51,700 shares; Mr. Magary, 60,000 shares; Mr. Pape, 57,000
shares; and directors and executive officers as a group, 1,838,500
shares.
(8) Based on information contained in the Schedule 13d dated May 17, 1995,
as amended November 13, 1995 and November 27, 1995, and filed jointly
with the Securities and Exchange Commission by Lion Advisors, L.P.
("Lion") and AIF II, L.P. ("AIF II"), such entities then owned
beneficially 381,135 common shares, including immediately exercisable
warrants to acquire 79,541 common shares. As of March 5, 1996, such
entities were issued an additional 137,724 common shares and warrants
to acquire 36,088 common shares. The managing general partner of AIF II
is Apollo Advisors, L.P. ("Advisors"). Advisors and Lion are
affiliates. Lion beneficially holds the indicated securities for an
investment account under management over which Lion has investment,
dispositive and voting power. The Company does not believe that Lion
and AIF II are affiliates of the Company under the Act.
(9) Represents immediately exercisable warrants to acquire 127,147 common
shares and 97,853 common shares acquired upon exercise of warrants
effective March 5, 1996.
(10) Shares that any person or group of persons is entitled to acquire upon
the exercise of options or warrants within 60 days after March 5, 1996,
are treated as issued and outstanding for the purpose of computing the
percent of the class owned by such person or group of persons but not
for
38
39
The Purpose of Computing the Percent of the Class Owned By Any Other
Person.
ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS
On April 6, 1994, the Company entered into settlement agreements with
each of Elekta Instruments, Inc. ("Elekta"), the manufacturer of the Gamma
Knife, and NME Hospitals, Inc., d/b/a USC University Hospital ("USC Hospital"),
the lessor of a Gamma Knife, to resolve disputes arising out of the Company's
inability to make a required progress payment under the agreement to purchase
such Gamma Knife. The settlement agreements required that the Company terminate
its original agreement to purchase the Gamma Knife from Elekta and to lease the
Gamma Knife to USC Hospital. Further conditions to execution of the settlement
agreements included that Dr. Bates, the Company's Chairman and Chief Executive
Officer, enter into a purchase agreement and lease agreement with Elekta and USC
Hospital, respectively, substantially identical to the respective terminated
agreements.
Pursuant to the new purchase agreement, Dr. Bates was entitled to
purchase the Gamma Knife from Elekta for an aggregate purchase price of
$2,900,000 plus sales tax. Dr. Bates obtained financing for the Gamma Knife
purchase from an unaffiliated third party. Dr. Bates' lender has financed the
total purchase price, less $290,000 advanced by the Company, pursuant to an
interest bearing installment note and security agreement. The Company has
advanced $290,000 of the purchase price, to be repaid by Dr. Bates over the term
of the new lease agreement, pursuant to a promissory note bearing interest at 6%
per annum and repayable over 60 months.
The Company and Dr. Bates entered into an option agreement entitling
the Company to purchase the Gamma Knife from Dr. Bates for an amount equal to
the remaining debt obligations associated with the Gamma Knife plus costs and
losses, if any, incurred by the Chief Executive Officer. This option was
assigned to GKF and exercised on February 3, 1996. In connection with the
exercise of the option by GKF, the interest bearing installment note was
cancelled.
On October 6, 1995, the Company entered into the Option Agreement with
its Chairman and Chief Executive Officer. Under the Option Agreement, Dr. Bates
was granted a ten-year option to purchase 1,495,000 Common Shares for an initial
exercise price of $0.01 per share. In addition, on May 17, 1995, as part of the
Notes Repurchase, the Company issued 184,000 Common Shares to Dr. Bates in
partial consideration of his personal guarantee of $6,500,000 of indebtedness of
the Company.
Willie R. Barnes, the Secretary and a director of the Company, is a
partner in the law firm of Musick, Peeler & Garrett. That law firm performed
legal services for the Company in 1995. The management of the Company is of the
opinion that the fees paid to Mr. Barnes' law firm are comparable to those fees
that would have been paid for comparable legal services from a law firm not
affiliated with the Company.
39
40
PART IV
ITEM 14. EXHIBITS, FINANCIAL STATEMENT SCHEDULES, AND REPORTS ON FORM 8-K
(a) Financial Statements and Schedules. the following financial
statements and schedules are filed with this report.
Report of Independent Auditors
Audited Consolidated Financial Statements
Consolidated Balance Sheets
Consolidated Statements of Operations
Consolidated Statements of Stockholders' Equity
(net capital deficiency)
Consolidated Statements of Cash Flows
Notes to Consolidated Financial Statements
Financial Statement Schedules
Valuation and Qualifying Accounts
All other schedules are omitted since the required information is
not present or is not present in amounts sufficient to require
submission of the schedule, or because the information required is
included in the financial statements and notes thereto.
Consent of Independent Auditors
(b) Exhibits. The following exhibits are filed with this report.
Exhibit
Number Description
3.1 Articles of Incorporation of the Company, as amended. (1)
3.2 By-laws of the Company, as amended. (2)
4.1 Indenture between American Shared Hospital Services and First
Interstate Bank of California, as Trustee, dated October 15, 1988,
relating to the Senior Subordinated Exchangeable Reset Notes Due 1996.
(1)
4.2 Indenture between American Shared Hospital Services and First
Interstate Bank of California, as Trustee, dated October 15, 1988,
relating to the 14-3/4% Senior Subordinated Notes Due 1996. (1)
4.3 Supplemental Indenture No. 1, dated as of October 15, 1989, to the
Indenture between American Shared Hospital Services and First
Interstate Bank of California, as Trustee, dated October 15, 1988,
relating to the Senior Subordinated Exchangeable Reset Notes Due 1996.
(3)
4.4 Supplemental Indenture No. 2, dated as of May 17, 1995, to the
Indenture between American Shared Hospital Services and First
Interstate Bank of California, as Trustee, dated October 15, 1988,
relating to the Senior Subordinated Exchangeable Reset Notes Due 1996.
(2)
4.5 Supplemental Indenture No. 1, dated as of May 17, 1995, to the
Indenture between American Shared Hospital Services and First
Interstate Bank of California, as Trustee, dated October 15, 1988,
relating to the 14- 3/4% Senior Subordinated Notes Due 1996. (2)
____________________
(1) These documents were filed as Exhibits 3.1, 4.1 and 4.2, respectively,
to registrant's Registration Statement on Form S-2 (Registration No.
33-23416), which is incorporated herein by this reference.
(2) These documents were filed as Exhibits 3.2, 4.4 and 4.5, respectively,
to registrant's Registration Statement on Form S-1 (Registration No.
33-63721) filed on October 26, 1995, which is incorporated herein by
this reference.
(3) This document was filed as Exhibit 4.3 to registrant's Annual Report
on Form 10-K for the fiscal year ended December 31, 1989, which is
incorporated herein by this reference.
40
41
4.6 Form of Common Stock Purchase Warrant held by Selling Noteholders of
American Shared Hospital Services. (1)
4.7 Common Stock Purchase Warrant for shares of Common Stock of American
Shared Hospital Services held by General Electric Company, acting
through GE Medical Systems, dated May 17, 1995. (1)
4.8 Registration Rights Agreement, dated as of May 17, 1995, by and among
American Shared Hospital Services, the Holders referred to in the Note
Purchase Agreement, dated as of May 12, 1995 and General Electric
Company, acting through GE Medical Systems. (1)
4.9 Promissory Note, dated May 17, 1995, by American Shared Hospital
Services in favor of General Electric Company in the principal sum of
$1,500,000, as amended. (1)
4.10 Promissory Note, dated January 31, 1996, by American Shared-CuraCare
and CuraCare, Inc. in favor of DVI Business Credit Receivables
Corporation, in the principal sum of $4,000,000. (2)
4.11 Promissory Note, dated May 17, 1995, by American Shared-CuraCare and
CuraCare, Inc. in favor of DVI Financial Services Inc. in the
principal sum of $2,500,000. (1)
4.12 Security Agreement dated as of May 17, 1995 by and between American
Shared Hospital Services and General Electric Company, acting through
GE Medical Systems. (1)
____________________
(1) These documents were filed as Exhibits 4.6, 4.7, 4.8, 4.9, 4.11, and
4.12, respectively, to registrant's Registration Statement on Form S-1
(Registration No. 33-63721) filed on October 26, 1995, which is
incorporated herein by this reference.
(2) This document was filed as Exhibit 4.10 to registrant's Pre-Effective
Amendment No. 1 to the Registration Statement on Form S-1
(Registration No. 33-63721) filed on March 29, 1996, which is
incorporated herein by this reference.
41
42
4.13 Agreement and Proxy, dated as of May 12, 1995 by Ernest A. Bates,
M.D., Accepted and Agreed to by Anchor National Life Insurance
Company, Sun Life Insurance Company of America, SunAmerica Inc., AIF
II, L.P., Lion Advisors, L.P., Grace Brothers, Ltd., and Upchurch
Living Trust U/A/D 12/14/90. (1)
4.14 Assignment and Assumption Agreement, dated as of December 31, 1995,
between American Shared Hospital Services (assignor) and American
Shared Radiosurgery Services (assignee). (2)
4.15 Assignment and Assumption Agreement, dated as of December 31, 1995,
between American Shared Radiosurgery Services (assignor) and GK
Financing, LLC (assignee). (2)
4.16 USC University Hospital Option Agreement, dated February 3, 1996,
among American Shared Hospital Services, Ernest A. Bates, M.D. and GK
Financing, LLC. (2)
4.17 Assignment and Assumption Agreement, dated as of February 1, 1996,
among Ernest A. Bates, M.D. (assignor) and GK Financing, LLC
(assignee). (2)
4.18 Assignment and Assumption Agreement, effective as of February 3, 1996,
among Ernest A. Bates, M.D. (assignor) and GK Financing, LLC
(assignee). (2)
4.19 Promissory Note, dated January 1, 1995, by American Shared-CuraCare in
favor of General Electric Company, acting through GE Medical Systems,
in the principal sum of $2,000,000, as amended. (2)
4.20 Promissory Note, dated December 30, 1994, by American Shared-CuraCare
in favor of General Electric Company, in the principal sum of
$481,667.81, as amended. (2)
____________________
(1) This document was filed as Exhibit 4.13 to registrant's Registration
Statement on Form S-1 (Registration No. 33-63721) filed on October 26,
1995, which is incorporated herein by this reference.
(2) These documents were filed as Exhibits 4.14, 4.15, 4.16, 4.17, 4.18,
4.19 and 4.20, respectively, to the registrant's Pre-Effective
Amendment No. 1 to registrant's Registration Statement on Form S-1
(Registration No. 33-63721) filed on March 29, 1996, which is
incorporated herein by this reference.
42
43
10.1 The Company's 1984 Stock Option Plan, as amended. (1)
10.2 The Company's 1995 Stock Option Plan. (2)
10.3 Form of Indemnification Agreement between American Shared Hospital
Services and members of its Board of Directors. (1)
10.4 Agreement, effective as of November 1, 1994, by and among General
Electric Company, acting through GE Medical Systems, and American
Shared Hospital Services, and certain of its subsidiaries as amended.
(3)
10.5 Note Purchase Agreement, dated as of May 12, 1995, by and among Anchor
National Life Insurance Company, Sun Life Insurance Company of
America, and SunAmerica Inc., AIF II, L.P., Lion Advisors, L.P., Grace
Brothers, Ltd. and Upchurch Living Trust U/A/D 12/14/90, American
Shared Hospital Services and Ernest A. Bates, M.D. (4)
10.6 Loan and Security Agreement, dated as of January 31, 1996, among
American Shared-CuraCare and CuraCare, Inc., American Shared Hospital
Services, Ernest A. Bates, M.D. and DVI Business Credit Receivables
Corporation. (5)
____________________
(1) These documents were filed as Exhibits 10.24 and 10.35, respectively,
to registrant's Registration Statement on Form S-2 (Registration No.
33-23416), which is incorporated herein by this reference.
(2) This document was filed as Exhibit A to registrant's Proxy Statement,
filed on August 31, 1995, which is incorporated herein by this
reference.
(3) This document was filed as Exhibit 10.49 to registrant's Annual Report
on Form 10-K for fiscal year ended December 31, 1994, which is
incorporated herein by this reference.
(4) This document was filed as Exhibit 10.5 to registrant's Registration
Statement on Form S-1 (Registration No. 33-63721) filed on October 26,
1995, which is incorporated herein by this reference.
(5) This document was filed as Exhibit 10.6 to registrant's Pre-Effective
Amendment No. 1 to the Registration Statement on Form S-1
(Registration No. 33-63721) filed on March 29, 1996, which is
incorporated herein by this reference.
43
44
10.7 Loan and Security Agreement, dated as of May 17, 1995, among American
Shared-CuraCare and CuraCare, Inc., American Shared Hospital Services,
Ernest A. Bates, M.D. and DVI Financial Services Inc. (1)
10.8 Form of Unconditional Continuing Guaranty of American Shared Hospital
Services.(2)
10.9 Form of Unconditional Continuing Guaranty of Ernest A. Bates, M.D. (2)
10.10 Intercreditor Agreement among American Shared Hospital Services,
American Shared-CuraCare, DVI Financial Services Inc. and DVI Business
Credit Receivables Corporation and General Electric Company, acting
through GE Medical Systems, dated as of January 31, 1996. (2)
10.11 Ernest A. Bates Stock Option Agreement dated as of August 15, 1995.
(3)
10.12 Operating Agreement for GK Financing, LLC, dated as of October 17,
1995. (1)
10.13 Amendments dated as of October 26, 1995 and as of December 20, 1995 to
the GK Financing, LLC Operating Agreement, dated as of October 17,
1995. (2)
____________________
(1) These documents were filed as Exhibits 10.7 and 10.12, respectively,
to registrant's Registration Statement on Form S-1 (Registration No.
33-63721) filed on October 26, 1995, which is incorporated herein by
this reference.
(2) These documents were filed as Exhibits 10.8, 10.9, 10.10 and 10.13,
respectively, to registrant's Pre- Effective Amendment No. 1 to the
Registration Statement on Form S-1 (Registration No. 33-63721) filed
on March 29, 1996, which is incorporated herein by this reference.
(3) This document was filed as Exhibit B to registrant's Proxy Statement,
filed on August 31, 1995, which is incorporated herein by this
reference.
44
45
21 Subsidiaries of American Shared Hospital Services. (1)
23.1 Consent of Ernst & Young LLP.
____________________
(1) This document was filed as Exhibit 21 to registrant's Pre-Effective
Amendment No. 1 to the Registration Statement on Form S-1
(Registration No. 33-63721) filed on March 29, 1996, which is
incorporated herein by this reference.
45
46
(C) REPORTS ON FORM 8-K.
The Company filed no reports on Form 8-K during the quarter ended
December 31, 1995.
46
47
SIGNATURES
Pursuant to the requirements of section 13 or 15(d) of the securities
exchange act of 1934, the registrant has duly caused this report to be signed on
its behalf by the undersigned, thereunto duly authorized.
American Shared Hospital Services
(Registrant)
April 1, 1996 By: /s/ Ernest A. Bates
--------------------
Ernest A. Bates, M.D.
Chairman and Chief
Executive Officer
Pursuant to the requirements of the securities exchange act of 1934, this
report has been signed below by the following persons on behalf of the
registrant in the capacities and on the dates indicated.
SIGNATURE TITLE DATE
- --------- ----- ----
/s/ Ernest A. Bates Chief Executive Officer April 1, 1996
- ------------------------
Ernest A. Bates Of The Board
Director And
- ------------------------
Willie R. Barnes Secretary
/s/ Matthew Hills Director April 1, 1996
- ------------------------
Matthew Hills
/s/John F. Ruffle Director April 1, 1996
- ------------------------
John F. Ruffle
/s/Stanley S. Trotman, Jr. Director April 1, 1996
- --------------------------
Stanley S. Trotman, Jr.
/s/Augustus A. White, III Director April 1, 1996
- --------------------------
Augustus A. White, III
/s/ Charles B. Wilson Director April 1, 1996
- --------------------------
Charles B. Wilson
/s/ James A. Gordin Acting Chief Financial April 1, 1996
- --------------------------
James A. Gordin Officer (Principal
Accounting Officer)
48
American Shared Hospital Services
Index to Consolidated Financial Statements
and Financial Statement Schedule (Item 14(a))
Years ended December 31, 1995, 1994 and 1993
CONTENTS
Report of Independent Auditors....................................... B-1
Audited Consolidated Financial Statements
Consolidated Balance Sheets.......................................... B-2
Consolidated Statements of Operations................................ B-3
Consolidated Statements of Stockholders' Equity
(Net Capital Deficiency)........................................... B-4
Consolidated Statements of Cash Flows................................ B-5
Notes to Consolidated Financial Statements........................... B-6
Financial Statement Schedule
Valuation and Qualifying Accounts.................................... B-21
All other schedules are omitted since the required information is not
present or is not present in amounts sufficient to require submission
of the schedule, or because the information required is included in
the financial statements and notes thereto.
Consent of Independent Auditors...................................... C-1
A-1
49
Report of Independent Auditors
The Board of Directors and Stockholders
American Shared Hospital Services
We have audited the accompanying consolidated balance sheets of American Shared
Hospital Services as of December 31, 1995 and 1994, and the related consolidated
statements of operations, stockholders' equity (net capital deficiency), and
cash flows for each of the three years in the period ended December 31, 1995.
Our audits also included the financial statement schedule listed in the Index at
Item 14(a). These financial statements and the schedule are the responsibility
of the Company's management. Our responsibility is to express an opinion on
these financial statements and the schedule based on our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of
material misstatement. An audit includes examining, on a test basis, evidence
supporting the amounts and disclosures in the financial statements. An audit
also includes assessing the accounting principles used and significant
estimates made by management, as well as evaluating the overall financial
statement presentation. We believe that our audits provide a reasonable basis
for our opinion.
In our opinion, the consolidated financial statements referred to above present
fairly, in all material respects, the consolidated financial position of
American Shared Hospital Services at December 31, 1995 and 1994, and the
consolidated results of its operations and its cash flows for each of the three
years in the period ended December 31, 1995, in conformity with generally
accepted accounting principles. Also, in our opinion, the related financial
statement schedule, when considered in relation to the basic financial
statements taken as a whole, presents fairly in all material respects the
information set forth therein.
The accompanying financial statements have been prepared assuming that American
Shared Hospital Services will continue as a going concern. As more fully
described in Note 1, the Company incurred substantial operating losses in 1995,
1994 and 1993 and has a significant working capital deficiency and a net capital
deficiency at December 31, 1995. These conditions raise substantial doubt about
the Company's ability to continue as a going concern. Management's plans in
regard to these matters are also described in Note 1. The financial statements
do not include any adjustments to reflect the possible future effects on the
recoverability and classification of assets or the amounts and classification of
liabilities that may result from the outcome of this uncertainty.
As discussed in Note 3 to the financial statements, in 1995 the Company adopted
Financial Accounting Standards Board Statement No. 121, "Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed Of."
ERNST & YOUNG LLP
February 20, 1996, except for Note 16,
as to which the date is March 8, 1996
Walnut Creek, California
B-1
50
AMERICAN SHARED HOSPITAL SERVICES
CONSOLIDATED BALANCE SHEETS
ASSETS
DECEMBER 31
-----------------------------
1995 1994
------------ ------------
CURRENT ASSETS:
Cash and cash equivalents..................................... $ 452,000 $ 1,225,000
Restricted cash............................................... 493,000 2,883,000
Receivables, less allowance for uncollectible accounts of
$1,448,000 ($1,424,000 in 1994):
Trade accounts receivable.................................. 6,251,000 6,183,000
Other...................................................... 202,000 537,000
Note receivable from officer............................... 57,000 54,000
----------- -----------
6,510,000 6,774,000
Inventories................................................... 67,000 146,000
Prepaid expenses and other current assets..................... 1,124,000 758,000
----------- -----------
Total current assets............................................ 8,646,000 11,786,000
Note receivable from officer, less current portion.............. 191,000 248,000
Property and equipment:
Land, buildings and improvements.............................. 1,560,000 2,351,000
Medical, transportation and office equipment.................. 7,453,000 9,670,000
Capitalized leased medical and transportation equipment....... 24,673,000 38,271,000
----------- -----------
33,686,000 50,292,000
Accumulated depreciation and amortization..................... 14,015,000 18,165,000
----------- -----------
Net property and equipment...................................... 19,671,000 32,127,000
Other assets.................................................... 1,462,000 943,000
Intangible assets, less accumulated amortization of $1,136,000
($1,386,000 in 1994).......................................... 1,375,000 2,118,000
----------- -----------
Total assets.................................................... $ 31,345,000 $ 47,222,000
=========== ===========
LIABILITIES AND STOCKHOLDERS' EQUITY (net capital deficiency)
Current liabilities:
Accounts payable........................................... $ 3,524,000 $ 4,450,000
Accrued interest........................................... 170,000 8,497,000
Employee compensation and benefits......................... 1,175,000 1,210,000
Other accrued liabilities.................................. 1,077,000 1,317,000
Current portion of long-term debt.......................... 2,796,000 3,079,000
Current portion of obligations under capital leases........ 5,924,000 8,135,000
Senior subordinated notes.................................. 773,000 18,467,000
----------- -----------
Total current liabilities....................................... 15,439,000 45,155,000
Long-term debt, less current portion............................ 9,278,000 2,539,000
Obligations under capital leases, less current portion.......... 16,847,000 21,705,000
Deferred income taxes........................................... 164,000 164,000
Minority interest............................................... 193,000 --
Stockholders' equity (net capital deficiency):
Common stock, without par value:
Authorized shares -- 10,000,000
Issued and outstanding shares -- 4,244,000 in 1995 and
2,867,000 in 1994.......................................... 10,635,000 8,795,000
Common stock options issued to officer........................ 2,414,000 --
Additional paid-in capital.................................... 930,000 763,000
Accumulated deficit........................................... (24,555,000) (31,899,000)
----------- -----------
Total stockholders' equity (net capital deficiency)............. (10,576,000) (22,341,000)
----------- -----------
Total liabilities and stockholders' equity (net capital
deficiency)................................................... $ 31,345,000 $ 47,222,000
=========== ===========
See accompanying notes.
B-2
51
AMERICAN SHARED HOSPITAL SERVICES
CONSOLIDATED STATEMENTS OF OPERATIONS
YEAR ENDED DECEMBER 31
---------------------------------------------
1995 1994 1993
------------ ----------- ------------
Revenues:
Medical services................................ $ 34,077,000 $38,545,000 $ 39,485,000
Costs and expenses:
Costs of operations:
Medical services payroll..................... 6,984,000 10,284,000 11,442,000
Maintenance and supplies..................... 6,766,000 7,808,000 7,431,000
Depreciation and amortization................ 8,302,000 9,504,000 7,715,000
Write-down of equipment...................... 3,825,000 -- 443,000
Equipment rental............................. 2,808,000 1,580,000 5,067,000
Other........................................ 3,990,000 4,969,000 4,973,000
Selling and administrative...................... 8,432,000 5,971,000 6,820,000
Interest........................................ 5,310,000 7,423,000 6,752,000
Write-down of intangible assets................. 600,000 -- 5,308,000
------------ ------------ ------------
Total costs and expenses.......................... 47,017,000 47,539,000 55,951,000
------------ ------------ ------------
(12,940,000) (8,994,000) (16,466,000)
Gain on sale of assets and early termination of
capital leases.................................. 226,000 3,294,000 124,000
Equity in earnings (losses) of partnerships....... 54,000 85,000 (51,000)
Interest and other income......................... 204,000 98,000 742,000
------------ ------------ ------------
Loss before income taxes and extraordinary item... (12,456,000) (5,517,000) (15,651,000)
Income tax expense (benefit)...................... 3,000 20,000 (7,000)
------------ ------------ ------------
Loss before extraordinary item.................... (12,459,000) (5,537,000) (15,644,000)
Extraordinary item -- gain on early extinguishment
of debt, net of income tax provision of $0 in
1995 and $7,000 in 1994......................... 19,803,000 362,000 --
------------ ------------ ------------
Net income (loss)................................. $ 7,344,000 $(5,175,000) $(15,644,000)
============ ============ ============
Primary earnings per share:
Loss before extraordinary item.................. $ (2.96) $ (1.93) $ (5.46)
Extraordinary item.............................. $ 4.71 $ .13 $ -
------------ ------------ ------------
Net income (loss)................................. $ 1.75 $ (1.80) $ (5.46)
============ ============ ============
Fully diluted earnings per share:
Loss before extraordinary item.................. $ (2.96) $ (1.93) $ (5.46)
Extraordinary item.............................. $ 4.71 $ .13 $ -
------------ ------------ ------------
Net income (loss)................................. $ 1.75 $ (1.80) $ (5.46)
============ ============ ============
Common shares and equivalents used in computing
per share amounts:
Primary...................................... 4,201,000 2,867,000 2,863,000
============ ============ ============
Fully diluted................................ 4,204,000 2,867,000 2,863,000
============ ============ ============
See accompanying notes.
B-3
52
AMERICAN SHARED HOSPITAL SERVICES
CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (NET CAPITAL DEFICIENCY)
COMMON
STOCK OPTIONS ADDITIONAL
COMMON COMMON ISSUED TO PAID-IN ACCUMULATED
SHARES STOCK OFFICER CAPITAL DEFICIT TOTAL
--------- ----------- ------------- ---------- ------------ ------------
Balances at December 31, 1992...... 2,845,000 $ 8,754,000 $ -- $ 175,000 $(11,080,000) $ (2,151,000)
Issuance of common stock......... 22,000 41,000 -- -- -- 41,000
Net loss......................... -- -- -- -- (15,644,000) (15,644,000)
--------- ----------- ---------- -------- ------------ ------------
Balances at December 31, 1993...... 2,867,000 8,795,000 -- 175,000 (26,724,000) (17,754,000)
Issuance of warrants to purchase
97,853 shares of common
stock......................... -- -- -- 588,000 -- 588,000
Net loss......................... -- -- -- -- (5,175,000) (5,175,000)
--------- ----------- ---------- -------- ------------ ------------
Balances at December 31, 1994...... 2,867,000 8,795,000 -- 763,000 (31,899,000) (22,341,000)
Issuance of warrants to purchase
216,000 shares of common
stock......................... -- -- -- 180,000 -- 180,000
Issuance of warrants to purchase
127,147 shares of common
stock......................... -- -- -- 156,000 -- 156,000
Issuance of warrants to purchase
98,000 shares of common
stock......................... -- -- -- 81,000 -- 81,000
Stock issuance costs............. -- -- -- (250,000) -- (250,000)
Issuance of common stock to
officer....................... 184,000 265,000 -- -- -- 265,000
Issuance of common stock to
bondholders................... 1,193,000 1,575,000 -- -- -- 1,575,000
Issuance of common stock options
to officer.................... -- -- 2,414,000 -- -- 2,414,000
Net income....................... -- -- -- -- 7,344,000 7,344,000
--------- ----------- ---------- -------- ------------ ------------
Balances at December 31, 1995...... 4,244,000 $10,635,000 $ 2,414,000 $ 930,000 $(24,555,000) $(10,576,000)
========= =========== ========== ======== ============ ============
See accompanying notes.
B-4
53
AMERICAN SHARED HOSPITAL SERVICES
CONSOLIDATED STATEMENTS OF CASH FLOWS
YEAR ENDED DECEMBER 31
----------------------------------------------
1995 1994 1993
------------ ------------ ------------
OPERATING ACTIVITIES
Net income (loss).......................................................... $ 7,344,000 $ (5,175,000) $(15,644,000)
Adjustments to reconcile net income (loss) to net cash provided by (used
in) operating activities:
Extraordinary gain, after income taxes................................. (19,803,000) (362,000) --
Gain on sale of assets................................................. (23,000) (3,294,000) (124,000)
Gain on early termination of capital leases............................ (203,000) -- --
Depreciation and amortization.......................................... 8,818,000 10,206,000 8,600,000
Write-down of equipment................................................ 3,825,000 -- 443,000
Write-down of intangible assets........................................ 600,000 -- 5,308,000
Equity in (earnings) losses of partnerships............................ (54,000) (85,000) 51,000
Compensation expense related to stock grants........................... 2,679,000 -- --
Changes in operating assets and liabilities:
Decrease (increase) in restricted cash............................... 2,390,000 (2,883,000) --
Decrease (increase) in receivables................................... 264,000 (573,000) 1,573,000
Decrease in inventories.............................................. 79,000 201,000 177,000
Decrease (increase) in prepaid expenses and other assets............. (366,000) (64,000) 212,000
(Decrease) increase in accounts payable and accrued liabilities...... (674,000) (335,000) 8,881,000
------------ ------------ ------------
Net cash provided by (used in) operating activities........................ 4,876,000 (2,364,000) 9,477,000
INVESTING ACTIVITIES
Proceeds from sale of respiratory therapy contracts........................ -- 4,002,000 --
Deposit on Gamma Knives.................................................... (1,000,000) -- --
Refund of deposit on Gamma Knife........................................... -- 1,090,000 --
Proceeds from sale and disposition of equipment............................ 157,000 900,000 1,005,000
Increase in minority interest.............................................. 193,000 -- --
Payment for purchase of property and equipment............................. (226,000) (393,000) (354,000)
Note receivable to related party........................................... -- (290,000) --
Distributions received from partnerships................................... 55,000 58,000 27,000
Other...................................................................... 200,000 -- (401,000)
------------ ------------ ------------
Net cash (used in) provided by investing activities........................ (621,000) 5,367,000 277,000
FINANCING ACTIVITIES
Principal payments on long-term debt and obligations under capital
leases................................................................... (9,612,000) (4,357,000) (10,264,000)
Issuance of restructuring notes............................................ -- 2,486,000 --
Proceeds from issuance of common stock..................................... -- -- 41,000
Repayment of advance for equipment purchase................................ -- (800,000) --
Proceeds from loan agreement............................................... 7,000,000 -- --
Note payable from related party............................................ 1,300,000 -- --
Payment for repurchase of senior subordinated notes........................ (3,893,000) (64,000) --
Other...................................................................... 177,000 -- --
------------ ------------ ------------
Net cash used in financing activities...................................... (5,028,000) (2,735,000) (10,223,000)
------------ ------------ ------------
Net (decrease) increase in cash and cash equivalents....................... (773,000) 268,000 (469,000)
Cash and cash equivalents at beginning of year............................. 1,225,000 957,000 1,426,000
------------ ------------ ------------
Cash and cash equivalents at end of year................................... $ 452,000 $ 1,225,000 $ 957,000
============ ============ ============
SUPPLEMENTAL CASH FLOW DISCLOSURE
Interest paid.............................................................. $ 3,625,000 $ 2,730,000 $ 1,613,000
============ ============ ============
Income taxes paid.......................................................... $ 82,000 $ 25,000 $ 27,000
============ ============ ============
SCHEDULE OF NONCASH INVESTING AND FINANCING ACTIVITIES
Purchases of equipment with lease financing................................ $ 1,342,000 $ 2,358,000 $ 5,100,000
(Decrease) increase in medical and capitalized lease equipment due to lease
restructuring............................................................ (480,000) 1,710,000 --
(Decrease) increase in capitalized lease obligations due to lease
restructuring............................................................ (480,000) 4,946,000 --
Decrease in accounts payable due to lease restructuring.................... -- 4,602,000 --
Decrease in capitalized lease obligations due to sale of respiratory
therapy contracts........................................................ -- (300,000) --
Accrued interest payable not paid as part of Senior Subordinated Notes
Repurchase............................................................... 8,853,000 -- --
Stock and warrants issued to bondholders as part of Senior Subordinated
Notes Repurchase......................................................... 1,836,000 588,000 --
Noncash portion of senior subordinated notes redemption.................... 13,801,000 257,000 --
See accompanying notes.
B-5
54
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
DECEMBER 31, 1995
1. BUSINESS AND BASIS OF PRESENTATION
Business
American Shared Hospital Services (the "Company") provides shared
diagnostic imaging services to hospitals located in approximately 22 states in
various geographic regions of the United States and to one hospital in the
United Kingdom. The four diagnostic imaging services provided by the Company are
Magnetic Resonance Imaging, Computed Axial Tomography Scanning, Ultrasound, and
Nuclear Medicine. In addition, the Company provides a Gamma Knife to a major
university medical center and in February 1996, acquired a second Gamma Knife
located in another major university medical center.
The consolidated financial statements include the accounts of the Company,
its wholly owned subsidiaries, CuraCare, Inc. ("CuraCare"), MMRI, Inc., European
Shared Medical Services Ltd., American Shared Radiosurgery Services ("ASRS"),
African American Church Health and Economic Services, Inc. ("ACHES"), ACHES
Insurance Services, Inc. ("AIS") and its majority-owned subsidiary, GK
Financing, LLC.
On October 17, 1995, the Company through ASRS and Elekta AB (the
manufacturer of the Gamma Knife), through its wholly owned United States
subsidiary GKV Investments, Inc. ("GKV"), entered into an operating agreement
which formed GK Financing, LLC ("GKF"). GKF provides alternative financing of
Elekta Gamma Knife units in the United States and in Brazil. GKF will be the
preferred provider for Elekta AB of financing arrangements such as
fee-for-service lease arrangements.
In June 1995, ACHES and AIS were incorporated. AIS is a wholly owned
subsidiary of ACHES. ACHES is an integrated health service organization to
develop and promote the delivery of high quality healthcare services, primarily
to the African American community. AIS is an insurance agency qualified to sell
life, health, and disability insurance in the states of California and New York.
All significant intercompany accounts and transactions have been eliminated
in consolidation.
The Company accounts for its investment in partnerships using the equity
method.
The Company faces severe competition from other providers of diagnostic
imaging services, some of which have greater financial resources than the
Company, and from equipment manufacturers, hospitals, imaging centers and
physician groups owning in-house diagnostic units. Significant competitive
factors in the diagnostic services market include equipment price and
availability, performance quality, ability to upgrade equipment performance and
software, service and reliability. The Company's current financial problems may
adversely affect its ability to obtain and retain certain profitable customer
contracts, and its current high debt burden may affect its ability to offer
technologically advanced equipment in the future. Due to the Company's financial
condition, the two stock exchanges which list the Company's stock have commenced
review procedures to determine whether the Company's common shares will remain
listed.
The Company leases substantially all of its medical equipment from one
primary provider.
Basis of Presentation
The Company has incurred net losses before extraordinary items of
$12,459,000, $5,537,000 and $15,644,000 in 1995, 1994 and 1993, respectively. At
December 31, 1995, the Company has a working capital deficiency of $6,793,000
and a net capital deficiency of $10,576,000. In addition, the Company will not
have sufficient cash resources to repay its debt obligations at maturity and
will be required to seek new financing. There can be no assurance that such
financing will be available or that the terms of any such financing will be
acceptable to the Company.
B-6
55
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
These conditions raise substantial doubt about the Company's ability to
continue as a going concern. These financial statements do not include any
adjustments to reflect the possible future effects on the recoverability and
classification of assets or the amounts and classification of liabilities that
may result from the possible inability of the Company to continue as a going
concern.
Management's plans with regard to these operating issues include the
following: Continue to implement its program of expense reductions; identify and
sell non-essential assets; negotiate favorable concessions from major creditors;
enhance revenues by increasing customer contracts and equipment utilization; and
offer to exchange equity in the Company in place of interest bearing debt. It is
uncertain as to whether these events will occur, and if they do, the extent to
which they will address the Company's operating issues.
2. ACCOUNTING POLICIES
Use of Estimates in the Preparation of Financial Statements
The preparation of the Consolidated Financial Statements of the Company
requires management to make estimates and assumptions that affect reported
amounts. These estimates are based on information available as of the date of
the financial statements. Actual results could differ from those estimates.
Cash and Cash Equivalents
The Company considers all highly liquid investments with original
maturities of three months or less at the date of purchase to be cash
equivalents. The Company maintains its cash in depository institutions which
offer varying levels of federal insurance. Restricted cash is not considered a
cash and cash equivalent for purposes of the Consolidated Statements of Cash
Flows.
Restricted Cash
Restricted cash represents cash limited as to use by a contractual
arrangement. Restricted cash at December 31, 1995 reflects cash that may only be
used for the operations of GK Financing, LLC. Restricted cash at December 31,
1994 represents cash pledged as collateral against borrowings under a now
extinguished loan agreement (see Note 7). This cash was used in 1995 to repay
the loan.
Revenues and Accounts Receivable
Revenue is recognized on a fee-for-service basis when the service is
delivered. Trade accounts receivable are principally from hospitals and other
health care providers located throughout the U.S., with no one customer
providing a significant percent of revenues. The Company's revenues from its
foreign operations comprised approximately 1% of total revenues. The Company
performs credit evaluations of its customers and generally does not require
collateral. The Company maintains an allowance for doubtful accounts at a level
which management believes is sufficient to cover potential credit losses. A
substantial portion of the Company's receivables collateralize its credit
facilities (see Note 7).
Accounting for Majority Owned Subsidiary
The Company accounts for GK Financing, LLC, as a consolidated entity due to
its majority ownership interest of 81%, which it acquired in exchange for its
contribution of assets with a net book value of $1,080,000 and fair value of
approximately $2,000,000 as of December 31, 1995. The increase between the net
book value and the fair value has been eliminated in consolidation. The minority
interest's 19% share of earnings (loss) is netted against "Equity in Earnings
(Losses) of Partnership" in the Statement of Operations.
B-7
56
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
Inventories
Inventories, which consist of minor medical equipment and supplies used in
the Company's business, are valued at the lower of cost or market, using a
valuation method which approximates FIFO (first-in, first-out).
Property and Equipment
In 1995, the Company adopted Statement of Financial Accounting Standards
No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to be Disposed Of" (see Note 3). As a result of such adoption, property
and equipment is stated at cost, or the estimated fair value as determined by
third parties, if less, as of December 31, 1995. In 1994, property and equipment
was stated at cost, or estimated net recoverable value if less.
Depreciation is determined using the straight-line method over the
estimated useful lives of the assets which are generally as follows:
Building and improvements............................... 25-40 years
Medical and transportation equipment.................... 2-10 years
Capitalized leased equipment consists primarily of mobile Magnetic
Resonance Imaging ("MRI") units, which include scanners and mobile vans.
Capitalized leased equipment is amortized over the term of the lease, which
range from 17 to 82 months. Leasehold improvements are amortized over the
shorter of the lease term or the estimated useful life.
Intangible Assets
Intangible assets represent the excess of cost of net assets acquired as
the result of the acquisition of businesses and are being amortized by the
straight-line method over 15 years. The Company annually assesses the
recoverability of these intangible assets by determining whether the
amortization of the intangible balance (for each business acquisition) over its
remaining life can be recovered through forecasted future operations using an
undiscounted cash flow methodology.
Income Taxes
The liability method is used to account for income taxes. Under this
method, deferred tax assets and liabilities are determined based on differences
between the financial reporting and tax bases of assets and liabilities and are
measured using the enacted tax rates and laws that will be in effect when the
differences are expected to reverse.
Per Share Amounts
Per share information has been computed based on the weighted average
number of common shares and dilutive common share equivalents outstanding.
Stock Options
The Company currently follows Accounting Principles Board Opinion No. 25,
"Accounting for Stock Issued to Employees" ("APB 25") and related
interpretations in accounting for its stock options. Under APB 25, because the
exercise price of the Company's employee stock options equals the market price
of the underlying stock on the date of grant, no compensation expense is
recognized. The Company intends to follow the provisions of APB 25 for future
years.
B-8
57
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
Fair Value of Financial Instruments
The fair value of financial instruments approximate their recorded values
except as discussed below.
An estimate of the fair value of the Company's long-term debt would require
the use of a discounted cash flow analysis based on the Company's current
incremental borrowing rates for similar types of borrowing arrangements.
Management believes that the Company's creditors entered into the borrowing
arrangements as a result of the personal guarantees of an officer of the Company
and believes that the Company would be unable to obtain similar financing given
this fact and the current state of its financial matters. Accordingly,
management is unable, without incurring excessive costs, to estimate its
incremental borrowing rate, and considers estimation of fair value to be
impracticable.
Reclassifications
Certain prior year balances have been reclassified to conform to the
current year presentation.
3. ADOPTION OF STATEMENT OF FINANCIAL ACCOUNTING STANDARDS NO.
121 -- "ACCOUNTING FOR THE IMPAIRMENT OF LONG-LIVED ASSETS AND FOR
LONG-LIVED ASSETS TO BE DISPOSED OF"
In connection with the adoption of statement of Financial Accounting
Standards No. 121 ("FAS 121"), during the second quarter of 1995, management
reviewed the recoverability of the carrying value of long-lived assets,
primarily fixed assets, goodwill and deferred costs based on the life of the
assets. The Company initiated its review of potential loss impairment due to the
continuing changes in the health care environment which have put downward
pressure on customer and equipment pricing. These changes have resulted in
recent operating results and revised future forecasted operating results for
certain assets to be less than previously planned. This situation led to the
conclusion that there was a potential impairment in the recorded value of fixed
assets, goodwill and deferred costs. Management's estimate of future
undiscounted cash flows over the useful life of certain assets was determined to
be less than their recorded values, indicating impairment of these assets under
the provisions of FAS 121. An impairment loss of $4,425,000 was recorded as of
the second quarter of 1995 based on the differences between the fair value, as
determined by third parties, and the recorded values of certain assets. The
impairment loss is comprised of write-downs of equipment of $3,825,000
(primarily MRI, CT, nuclear medicine, and deferred assets); and a write-down of
goodwill of $600,000.
4. WRITE-DOWN OF INTANGIBLE ASSETS AND PROPERTY AND EQUIPMENT
During 1993, the Company's management continued to evaluate the
realizability of intangible assets recorded in connection with its acquisition
of CuraCare in 1987, which subsidiary conducts substantially all of the
Company's non-MRI operations, including CT scanning, respiratory therapy,
ultrasound and nuclear medicine. Revenues and operating profits from CuraCare,
continued to decline despite several strategic plans implemented by management.
In the fourth quarter of 1993, management continued to evaluate its non-MRI
operations and determined that significant revenue growth was unlikely and
reduced its operations management and sales force accordingly. These conditions
helped to contribute to higher than expected losses in 1992 and 1993 and an
accumulated deficit at December 31, 1993, before the write-off of goodwill. The
Company determined, based on its methodology of evaluating the recoverability of
goodwill, that the forecasted results of operations for non-MRI operations
(which were based on historic financial trends and current market conditions)
did not support the future amortization of the recorded goodwill balance of
$5,308,000 at December 31, 1993, for these modalities.
The methodology employed to assess the recoverability of the Company's
goodwill was to forecast results of operations, including interest expense,
forward five years. The Company then evaluated the recoverability of
B-9
58
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
goodwill on the basis of these forecasts of future operations. In formulating
the financial forecasts, the Company considered the near-term, as well as the
longer-term business outlook. These near-term forecasts took into consideration
recent historical financial results and current market conditions, as well as
foreseeable opportunities for future growth. For the longer-term, the Company
also considered the possible emergence of new trends and their potential
impact upon each of the modalities. Based on such forecasts, the cumulative
results of operations for non-MRI operations were insufficient to recover any
portion of the respective goodwill balances. Accordingly, the Company wrote
off its remaining goodwill balances for these operations of $5,308,000 in the
fourth quarter of 1993.
Also during 1993, the Company experienced a decline in the market
acceptance of certain of its less advanced MRI and CT scanning equipment.
Accordingly, the Company reduced the carrying value of this equipment to the
Company's estimate of the future revenue generating capacities of the equipment.
This write-down resulted in a charge to operations of $443,000 in 1993.
5. OTHER ASSETS
Other assets consist of the following:
DECEMBER 31
-----------------------
1995 1994
---------- --------
Deposit on Gamma Knives...................................... $1,000,000 $ --
Capitalized regulatory licensing fees........................ 70,000 212,000
Prepaid commissions.......................................... 114,000 --
Debt issuance costs, less accumulated amortization of $0 and
$950,000 in 1995 and 1994, respectively.................... -- 129,000
Purchased software, less accumulated amortization of $558,000
and $471,000 in 1995 and 1994, respectively................ 42,000 110,000
Investment in partnerships................................... 59,000 60,000
Capitalized stock issuance costs............................. -- 327,000
Other, less allowance of $0 in 1995 and $165,000 in 1994..... 177,000 105,000
---------- --------
$1,462,000 $943,000
========== ========
6. SENIOR SUBORDINATED NOTES
In 1988, the Company completed a concurrent public common stock and debt
offering consisting of $30,000,000 of senior subordinated exchangeable reset
notes (the "Senior Subordinated Notes") due in 1996. The Senior Subordinated
Notes bore interest at an initial rate of 14% per annum payable semiannually
commencing April 15, 1989. On October 15, 1989, the interest rate on the Senior
Subordinated Notes not previously exchanged, as described below, was reset to
16.5%.
Prior to the October 15, 1989 reset date, $2,140,000 of Senior Subordinated
Notes were exchanged into 14.75% senior subordinated notes due 1996. Except for
the interest rate, optional and mandatory redemption provisions of the Senior
Subordinated Notes and the fact that the 14.75% Senior Subordinated Notes were
not exchangeable, the terms of the 14.75% Senior Subordinated Notes are
substantially the same as the terms of the Senior Subordinated Notes. The
Company may redeem all or part of the Senior Subordinated Notes for 100% of the
principal amount, together with accrued and unpaid interest to the redemption
date.
B-10
59
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
During 1995 and 1994, the Company repurchased certain of its Senior
Subordinated Notes resulting in extraordinary gains of $19,803,000 and $362,000
as follows:
1995 1994
----------- --------
Principal amount of Notes repurchased....................... $17,694,000 $321,000
Accrued interest related to the Notes....................... 8,853,000 115,000
Unamortized debt issuance costs............................. (525,000) (3,000)
Stock and warrants issued to bond holders................... (1,836,000) --
Estimated tax liability..................................... -- (7,000)
Closing costs............................................... (490,000) --
----------- --------
23,696,000 426,000
Payment for repurchase...................................... (3,893,000) (64,000)
----------- --------
Extraordinary gain.......................................... $19,803,000 $362,000
=========== ========
On May 12, 1995, the Company entered into a debt restructuring agreement
with four holders of $17,694,000 face value of its Senior Subordinated Notes. On
May 17, 1995, these Senior Subordinated Note holders received approximately
$3,900,000 in cash, plus 819,000 shares of common stock (equal to approximately
20% of the Company's then fully diluted outstanding shares), and warrants for an
additional 216,000 shares of common stock (equal to approximately 5% of the then
fully diluted common shares). The warrants are immediately exercisable at $0.75
per share. The remaining Senior Subordinated Noteholders hold $773,000 of the
notes as of December 31, 1995 and as a result of the restructuring, were paid
their past due accrued interest. In addition, the debt covenants were amended
which thereby cured the events of default on the Senior Subordinated Notes.
Concurrent with the closing of the Senior Subordinated Notes repurchase in
1995, the Company obtained three new credit facilities totaling $8,000,000 of
which $7,000,000 was originally drawn (see Note 7). Proceeds from the new credit
facilities were used as follows:
Repurchase of Senior Subordinated Notes.................................. $3,900,000
Reduction of other term debt............................................. 400,000
Closing costs............................................................ 570,000
Refinance of certain equipment........................................... 1,000,000
Payment of accrued and unpaid interest through April 15, 1995 to
remaining bondholders.................................................. 500,000
Working capital.......................................................... 630,000
----------
Total originally drawn................................................... $7,000,000
==========
Closing costs include approximately $80,000 of loan origination fees which
have been capitalized.
B-11
60
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
7. LONG-TERM DEBT
Long-term debt consists of the following:
DECEMBER 31
---------------------------
1995 1994
----------- -----------
Notes Issued in Conjunction with Lease Restructuring
Promissory note payable to primary provider of medical
equipment bearing interest at 4%, payable in 86 monthly
installments due in February 2002, secured by the
Company's accounts receivable and certain medical
equipment............................................... $ 1,976,000 $ 2,000,000
Promissory note payable to primary provider of medical
equipment bearing interest at 10.5%, payable in 60
monthly installments due in February 2000............... 404,000 481,000
Borrowings for Repurchase of Senior Subordinated Notes
Borrowings under $4 million Revolving Line of Credit
bearing interest at prime rate plus 5% (13.5% at
December 31, 1995) for repurchase of senior subordinated
notes maturing in May 1997.............................. 3,883,000 --
Borrowings under Term Loan for repurchase of senior
subordinated notes bearing interest at 15%, payable in
48 monthly installments due in June 1999................ 2,305,000 --
Gamma Knife loan payable to primary provider of medical
equipment bearing interest at 10.5%, payable in 40
monthly installments due in September 1998.............. 1,135,000 --
Borrowings under former loan agreement for repurchase of
senior subordinated notes (repaid in 1995).............. -- 2,883,000
Other Notes and Borrowings
Promissory note payable to related party, bearing interest
at prime rate plus 2% (10.5% at December 31, 1995)
$1,000,000 due in October 1996 and $300,000 due in
October 1997 (Note 15).................................. 1,300,000 --
Promissory note payable to related party in the amount of
$1,320,000, bearing interest at prime rate plus 2%
(10.5% at December 31, 1995) maturing in October 1997
for capital expenditures relating to GK Financing, LLC.
No amounts outstanding (Note 15)........................ -- --
Installment notes payable in monthly installments through
January 1999, bearing interest at 10.5% to 22%, secured
by certain medical equipment............................ 836,000 242,000
Promissory note payable bearing interest at 11.25%,
payable in 25 monthly installments due in July 1997..... 235,000 --
Other..................................................... -- 12,000
---------- ----------
12,074,000 5,618,000
Less current portion...................................... (2,796,000) (3,079,000)
---------- ----------
$ 9,278,000 $ 2,539,000
========== ==========
Annual contracted maturities under the initial terms of long-term debt for
the five years after December 31, 1995 are as follows: $2,796,000 in 1996,
$6,043,000 in 1997, $1,695,000 in 1998, $868,000 in 1999, $350,000 in 2000 and
$322,000 thereafter.
The Company is severely limited by covenants in its credit agreements which
limit the Company's ability to merge with any other entity, to create
subsidiaries, to pay cash dividends, to repurchase stock for cash, incur
B-12
61
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
additional indebtedness, or to change the status of the equipment acting as
collateral in such a way as to impair its value.
In addition, the Company has pledged substantially all of its liquid assets
and substantially all of its personal property to secure its existing debt.
Notes Issued in Conjunction with Lease Restructuring
On December 30, 1994 the Company converted various service and other
payments that were due and unpaid into a $2,000,000 promissory note with its
primary provider of medical equipment. The note is dated January 1, 1995 and was
issued by the Company in conjunction with the lease restructuring (see Note 11).
The note matures in February 2002 and bears interest at an annual rate of 4%
payable in arrears. Monthly payments of interest only are due for the first
eleven months through November 1995. Thereafter, the principal balance of the
note will amortize in 75 equal monthly installments until maturity. The note is
secured by a second priority lien on the accounts receivable of the Company and
a first priority lien on certain medical equipment.
The Company also converted $481,000 of unpaid use taxes into a note payable
to its primary provider of medical equipment. The note bears interest at 10.5%
payable in 60 monthly payments beginning February 1, 1995.
Borrowings for Repurchase of Senior Subordinated Notes
The repurchase of Senior Subordinated Notes was completed with the proceeds
of three new credit facilities: a new Revolving Line of Credit (the "New
Revolver"), a term loan, and a Gamma Knife Loan. Under the New Revolver, the
Company has available up to $4,000,000 according to a formula based on eligible
accounts receivable. The New Revolver provides for interest payments only
(computed at the Bank of America prime rate plus 5%, 13.5% at December 31, 1995)
until maturity on May 31, 1997, when all amounts are due and payable. The
initial proceeds of $3,000,000 drawn under the New Revolver were used primarily
to fund the cash consideration in the Notes Repurchase. At December 31, 1995,
the Company had drawn $3,883,000 under the New Revolver and, based on eligible
accounts receivable, had an additional $117,000 available under the facility.
Under the terms of the agreement, the Company's cash receipts are processed
through bank accounts controlled by the lender and the lender has a first
priority lien on all of the Company's accounts receivable, certain equipment,
inventory and general intangibles. The New Revolver is personally guaranteed by
an officer of the Company.
The Company also entered into a $2,500,000 four-year loan agreement that
will amortize in 48 equal installments with interest at an annual rate of 15%
(the "Term Loan"). The Term Loan is secured by a first priority lien on certain
equipment, inventory and certain real property of the Company and a second
priority lien on the Company's accounts receivable and general intangibles. In
addition to funding the repurchase of the Subordinated Notes, the proceeds of
the Term Loan were applied to the refinancing of certain medical imaging
equipment and to provide working capital to the Company. The Term Loan is also
guaranteed by an officer of the Company.
The Company also entered into a $1,500,000 18-month level amortizing loan
at an interest rate of 10.5% (the "Gamma Knife Loan"). The proceeds of the Gamma
Knife Loan were used to refinance the Company's Gamma Knife, to fund in part the
Notes Repurchase, and to provide working capital. The Gamma Knife Loan is
collateralized with a first priority security interest in the Gamma Knife owned
by the Company. The payments on this loan were restructured in September 1995
from $90,431 per month to $40,203 per month
B-13
62
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
effective September 17, 1995, and to extend the loan term to September 17, 1988,
to match renegotiated terms of the underlying customer contracts.
In March 1991, the Company entered into a loan agreement (as amended),
which initially expired in March 1993 and was extended for periodic terms
through February 1995, under which it could generally borrow up to 66% of
eligible accounts receivable, reduced to 50% if total borrowings equal or exceed
$4,000,000, up to a maximum of $5,000,000. Proceeds from loans under the
agreement could only be used to repurchase the Company's senior subordinated
notes. Borrowings under the agreement bore interest at the prime rate plus 4%,
payable monthly.
On December 31, 1994, with the proceeds from the sale of certain of the
Company's respiratory therapy contracts (see Note 13), the Company deposited
$2,883,000 cash as collateral with the lender. On February 28, 1995, the cash
collateral was applied against the outstanding borrowings and this loan
agreement was terminated.
8. INCOME TAXES
Significant components of the Company's deferred tax liabilities and assets
as of December 31, 1995 and 1994 are as follows:
1995 1994
------------ ------------
Deferred tax liabilities:
Other -- net.................................................. $ (164,000) $ (164,000)
--------- ---------
Total deferred tax liabilities.................................. (164,000) (164,000)
Deferred tax assets:
Net operating loss carryforwards.............................. 6,400,000 9,960,000
Fixed assets.................................................. 2,900,000 1,800,000
Other -- net.................................................. 600,000 800,000
--------- ---------
Net deferred tax assets......................................... 9,900,000 12,560,000
Valuation allowance for deferred tax assets..................... (9,900,000) (12,560,000)
--------- ---------
Total deferred tax assets....................................... -- --
--------- ---------
Net deferred tax liabilities.................................... $ (164,000) $ (164,000)
========= =========
The decrease in the valuation allowance during 1995 was $2,660,000.
The components of the provision (benefit) for income taxes consist of the
following:
DEFERRED
LIABILITY METHOD METHOD
------------------ --------
1995 1994 1993
------ ------- --------
Current:
Federal................................................ $ -- $ -- $ --
State.................................................. 3,000 27,000 (7,000)
Deferred (reduction):
Federal................................................ -- -- --
State.................................................. -- -- --
------ ------- -------
$3,000 $27,000 $ (7,000)
====== ======= =======
B-14
63
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
The amounts relate to state income taxes, miscellaneous payments and
refunds of federal and state income taxes and adjustments of amounts paid and
accrued in prior years.
The provision (benefit) for income taxes as included in the consolidated
financial statements is as follows:
1995 1994 1993
------ ------- -------
Income (loss) before extraordinary gain................ $3,000 $20,000 $(7,000)
Extraordinary gain..................................... -- 7,000 --
------ ------- -------
$3,000 $27,000 $(7,000)
====== ======= =======
The provision (benefit) for income taxes differs from the amount computed
by applying the U.S. federal statutory tax rate (35% in 1995, 1994 and 1993) to
income (loss) before taxes as follows:
1995 1994 1993
----------- ----------- -----------
Computed expected tax, including tax on
extraordinary gain........................ $ 2,570,000 $(1,802,000) $(5,478,000)
Change in valuation allowance............... (2,660,000) 1,735,000
State income taxes (benefit), net of federal
benefit................................... 3,000 27,000 (7,000)
Amortization and write-down of intangible
assets.................................... 77,000 67,000 2,067,000
Limitation of net operating loss
carryback................................. -- -- 3,386,000
Other....................................... 13,000 -- 25,000
---------- ----------- -----------
$ 3,000 $ 27,000 $ (7,000)
========== =========== ===========
At December 31, 1995, the Company has a net operating loss carryforward for
federal income tax return purposes of approximately $18,000,000 which expires
between 1999 and 2009. This carryforward is subject, in part, to separate return
limitations. The Company's ability to utilize the net operating loss
carryforward may be limited in the event of a 50% or more ownership change
within any three-year period. Approximately $19,800,000 of the previous net
operating loss carryforward was used to offset the gain on early extinguishment
of the senior subordinated notes in May 1995.
9. STOCKHOLDERS' EQUITY
1984 Stock Option Plan
Under the Company's 1984 Stock Option Plan (the "Plan"), as amended, a
total of 475,000 stock options were authorized for grant. The Plan terminated
according to its terms on March 1, 1994. Options granted pursuant to the Plan
generally had lives of 10 years from the date of grant, subject to earlier
expiration in certain cases, such as termination of the grantee's employment.
On August 15, 1995, the Stock Option Committee of the Board of Directors
approved the amendment of the terms of substantially all options outstanding
under the Company's 1984 Stock Option Plan, covering an aggregate of
approximately 165,000 common shares, to reduce the initial exercise price to
$1.625 per common share, which was the closing price of common shares on such
date.
1995 Stock Option Plan
On August 15, 1995, the Board of Directors approved the Company's 1995
Stock Option Plan (the "1995 Plan") providing for non-qualified stock options
and "incentive stock options," subject to approval by the Company's
shareholders. At the 1995 Annual Meeting held on October 6, 1995, the
shareholders approved the
B-15
64
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
1995 Plan. Under the 1995 Plan, 330,000 Common Shares have been reserved for
awards to officers and other key employees, non-employee directors and advisors.
Approximately six employees, one advisor, and five non-employee directors
currently participate in the 1995 Plan. The 1995 Plan is administered by the
Stock Option Committee of the Board of Directors.
On August 15, 1995, the Stock Option Committee of the Board of Directors
approved the grant of 243,500 options under the Plan, subject to shareholder
approval. Additional grants of 12,000 were made to the Board of Directors under
the terms of the Plan. All such options are immediately exercisable at an
exercise price of $1.625 per share, which was the closing price of common shares
on such date.
Changes in options outstanding under the 1984 and 1995 Stock Option Plans
from December 31, 1992 to December 31, 1995 are as follows:
NUMBER EXERCISE PRICE
OF SHARES PER SHARE
--------- ---------------
Options outstanding at December 31, 1992................. 385,000 $ 1.38 - $7.50
Granted................................................ 93,000 $3.375 - $3.875
Exercised.............................................. (22,000) $1.875
Forfeited.............................................. (148,000) $ 1.875 - $6.50
-------
Options outstanding at December 31, 1993................. 308,000 $ 1.38 - $7.50
Granted................................................ -- --
Exercised.............................................. -- --
Forfeited.............................................. (52,000) $ 1.38 - $5.00
-------
Options outstanding at December 31, 1994................. 256,000 $ 1.38 - $7.50
Granted................................................ 256,000 $1.625
Exercised.............................................. -- --
Forfeited.............................................. (92,000) $ 3.00 - $7.125
-------
Options outstanding at December 31, 1995................. 420,000
Outstanding options exercisable at:
December 31, 1993...................................... 213,000 $ 1.38 - $7.50
=======
December 31, 1994...................................... 190,000 $ 1.38 - $7.50
=======
December 31, 1995...................................... 375,000 $ 1.38 - $1.625
=======
Options available for grant at December 31, 1995......... 74,000
=======
Warrants Issued in Conjunction with Lease Restructuring
On December 30, 1994, as partial consideration for the financial
accommodations granted in the restructuring of the Company's lease obligations,
the Company issued immediately exercisable warrants to its primary provider of
leased equipment granting the right to purchase 97,853 common shares at a price
of $0.01 per share until March 31, 1996.
On May 17, 1995, simultaneous with the Notes repurchase (Note 6), the
Company issued additional warrants to its primary provider of leased equipment
granting the right to purchase 127,147 common shares at a price of $0.01 per
share until September 30, 1996.
B-16
65
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
Options and Warrants Issued in Conjunction with Repurchase of Senior
Subordinated Notes
On May 17, 1995, simultaneous with the Notes repurchase (Note 6), the
Company issued 819,000 common shares (equal to approximately 20% of the
Company's then fully diluted common shares) and warrants to purchase 216,000
shares of common stock (equal to approximately 5% of the then fully diluted
common shares) to the holders of $17,694,000 face value of the Company's Senior
Subordinated Notes that were repurchased (the "ex-Noteholders"). The warrants
are immediately exercisable at $0.75 per share, expiring on May 17, 2002.
As a result of the additional options awarded to an officer of the Company,
the ex-Noteholders were granted 374,000 additional common shares and 98,000
additional warrants to purchase common shares, to maintain their ownership
interest at approximately 25% of the Company's then fully diluted common shares.
The warrants are immediately exercisable at $0.75 per share expiring on May 17,
2002.
Shares and Options Issued to Officer
Simultaneous with the Notes repurchase (Note 6), the Company's Chairman and
Chief Executive Officer, was issued an additional 184,000 shares of the
Company's common stock, which the Company has recorded as compensation expense
of $265,000. The common shares were granted to the officer in partial
consideration for a personal guarantee of $6.5 million of new credit facilities
and for continued employment with the Company.
In addition, on October 6, 1995, the officer was granted a ten-year
immediately exercisable option to purchase 1,495,000 common shares for an
exercise price of $0.01 per share which the Company has recorded as compensation
expense of $2,414,000. These options were granted to the officer as the final
consideration for personal guarantees of the new credit facilities and for
continued employment with the Company.
Capital shares reserved for future issuances total 2,529,000 shares at
December 31, 1995.
10. RETIREMENT PLAN
The Company has a defined contribution retirement plan which covers
substantially all employees. Under the terms of the plan, the Company may
contribute a discretionary matching contribution on behalf of each participant,
determined each year by the Company, equal to a percentage of each participant's
contributions and applicable to the first 6% of each participant's salary. The
Company made no contributions to the plan in 1995, 1994 or 1993.
11. OBLIGATIONS UNDER CAPITAL LEASES
The Company leases MRI units and other equipment under capital leases
having an aggregate net book value of $17,093,000 at December 31, 1995.
Amortization of assets recorded under capital leases is included with
depreciation expense, and is primarily amortized over the life of the lease.
On December 30, 1994 (effective as of November 1, 1994 for most leases that
were considered capital prior to that date and January 1, 1994 for operating
leases that were considered operating leases prior to that date) and again at
the end of 1995 the Company and its major provider of medical equipment entered
into a restructuring of the obligations of the Company under lease agreements.
Substantially all equipment financed by the Company under capital leases
was restructured and after restructuring continued to meet the criteria to be
accounted for as capitalized leases. Under these modified leases, required
payments by the Company are scheduled to retire the unpaid principal balance
over the extended lease terms which will expire on various dates through
December 31, 1999. All the operating leases
B-17
66
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
covered by the restructuring agreement in effect on October 31, 1994 were
modified to extend the payment schedules. As a result of modification of lease
terms, these leases met the criteria for capitalization, and were accounted for
as capital leases in the accompanying financial statements. Under all the
modified leases the Company is entitled to purchase the equipment at its fair
market value, or to extend the relevant lease, at the end of the lease term.
The modified leases, as identified above, were further restructured
effective October 1, 1995. No payments were required for the months of October
through December 1995. During these months interest was accrued and was added to
the outstanding principal balance of the capital leases. In addition, the leases
were extended up to an additional 26 months, where possible, to coincide with
the probable termination of the Company's end user contracts. After this
restructuring, the modified leases continue to meet the criteria to be accounted
for as capitalized leases. Under all the modified leases, the Company will be
entitled to purchase the equipment at its fair value or to extend the relevant
lease at the end of the lease term.
Future minimum lease payments, together with the present value of the net
minimum lease payments under capital leases at December 31, 1995, are summarized
as follows:
1996.................................................... $ 8,313,000
1997.................................................... 7,871,000
1998.................................................... 6,792,000
1999.................................................... 4,211,000
2000.................................................... 985,000
-----------
Net minimum lease payments.............................. 28,172,000
Less amounts representing interest...................... (5,401,000)
-----------
Present value of net minimum lease payments............. 22,771,000
Less current portion.................................... (5,924,000)
-----------
$16,847,000
===========
In addition to the above capital lease payments, the Company is also
required to make repair, maintenance, and other lease related payments. These
payments vary primarily on the level and amount of repairs and service needed.
The estimated minimum payments under these agreements are approximately
$1,847,000, $1,820,000, $633,000, $253,000 and $59,000 from the years 1996 to
2000, respectively.
During 1995, 1994 and 1993, the Company financed approximately $1,342,000,
$2,358,000 and $5,100,000, respectively, of equipment purchases with capital
lease obligations. During 1995, 1994 and 1993, the Company incurred interest
costs of $5,310,000, $7,423,000 and $6,828,000, respectively, including
capitalized interest related to construction in progress of $-0- in 1995, $-0-
in 1994 and $76,000 in 1993.
12. OPERATING LEASES
The Company leases MRI and CT scanning equipment, automobiles,
transportation equipment, office space, and facilities to service and operate
scanners under operating leases expiring at various dates through 2000.
B-18
67
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
Future minimum payments under noncancelable operating leases having initial
terms of more than one year consisted of the following at December 31, 1995:
1996..................................................... $ 834,000
1997..................................................... 783,000
1998..................................................... 764,000
1999..................................................... 605,000
2000..................................................... 207,000
----------
$3,193,000
==========
Payments for repair and maintenance agreements are included in the future
minimum operating lease payments shown above.
Rent expense was $3,458,000, $2,326,000 and $6,083,000 for the years ended
December 31, 1995, 1994 and 1993, respectively, and includes the above operating
leases as well as month-to-month rental and certain capital lease executory
costs.
13. SALE OF RESPIRATORY THERAPY CONTRACTS
The Company sold eight of fourteen respiratory therapy contracts to an
unrelated third party on December 31, 1994 for approximately $4,000,000 in cash.
As a result of the sale, the Company wrote off $180,000 in assets relating to
the contracts. In addition, the purchaser agreed to assume $300,000 in lease
obligations related to the assets. The Company recognized a gain on this
transaction of $3,199,000. Revenues generated under these contracts was
approximately $5,300,000 in 1994. A net loss in 1994 of $400,000 was recognized
on the operation of these contracts on a fully costed basis. The sale of the
contracts constitutes a sale of a portion of a product line in which the Company
is reducing its emphasis.
14. NOTE RECEIVABLE FROM OFFICER
At December 31, 1994, the Company had advanced $290,000 to the Chief
Executive Officer who executed a promissory note payable to the Company. The
note bears interest at 6% and is payable in 60 monthly fully amortizing payments
beginning in January 1995. Interest income recognized in conjunction with the
note was $15,000 and $12,000 during 1995 and 1994, respectively.
15. COMMITMENTS AND CONTINGENCIES
On April 6, 1994, the Company's agreements to purchase a Gamma Knife from
an equipment manufacturer and lease the Gamma Knife to a hospital were
terminated. As a settlement, the Company paid approximately $130,000 in interest
and costs to the parties and the Company's Chief Executive Officer agreed to
enter into purchase and lease obligations substantially identical to those
previously entered into by the Company. The Manufacturer has agreed to sell the
Gamma Knife to, and the hospital agreed to lease the Gamma Knife from, the
Company's Chief Executive Officer. Of the $1,090,000 in deposits previously paid
to the Manufacturer, $800,000 was returned to the third party lessor and
$290,000 previously paid by the Company was advanced by the Company to the Chief
Executive Officer who executed a promissory note payable (see Note 13).
Concurrently, the third party lessor agreed to fund the remaining $2,610,000
purchase price of the Gamma Knife on behalf of the Chief Executive Officer and
the Company received an option to purchase the Gamma Knife from the Chief
Executive Officer for an amount equal to the remaining debt obligation
associated with the Gamma Knife plus costs and operating losses, if any, on the
Gamma Knife (see Note 16).
B-19
68
AMERICAN SHARED HOSPITAL SERVICES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
DECEMBER 31, 1995
On October 17, 1995, the Company through its 81% owned subsidiary, GK
Financing, LLC, entered into a quotation agreement to purchase four Gamma Knife
units from the equipment manufacturer. Under the terms of the quotation
agreement, the Company is committed to purchase this equipment for $11,744,000,
effective when the equipment is placed in service at a customer location. At
December 31, 1995, the Company had a $1,000,000 deposit related to this purchase
commitment which was classified as part of other assets. The equipment
manufacturer is a 19% owner of GK Financing, LLC, and provided the promissory
note payable of $1,300,000, $1,000,000 of which was subsequently used to make
the deposit on the equipment. Additionally, GK Financing, LLC signed another
promissory note for $1,320,000 with the equipment manufacturer to provide funds
for future capital expenditures. As of December 31, 1995 there have been no
borrowings under this note.
16. SUBSEQUENT EVENTS
Assignment and Exercise of Option to Purchase Gamma Knife
On February 3, 1996, the Company assigned its option to purchase the Gamma
Knife from the Chief Executive Officer (see Note 15) to its subsidiary GK
Financing, LLC; which then exercised the option to purchase the Gamma Knife.
Exercise of Warrants
The primary provider of leased equipment exercised 97,853 warrants at a
price of $.01 per share on March 5, 1996 (see Note 9).
Lease and Note Payable Restructuring
On March 1, 1996, the Company received an offer from its primary provider
of medical equipment to restructure certain of its capital lease obligations, as
well as its promissory note payable in the amount of $1,976,000 at December 31,
1995. The general terms of the restructuring provide for various months of no
payments in 1996 followed by increased payments in the latter part of the
agreements. The Company completed this restructuring on March 8, 1996.
B-20
69
SCHEDULE 5.02(4)
AMERICAN SHARED HOSPITAL SERVICES
VALUATION AND QUALIFYING ACCOUNTS
ADDITIONS
CHARGED ADDITIONS ADDITIONS
BALANCE AT TO BALANCE AT CHARGED TO BALANCE AT CHARGED TO
DECEMBER 31, COSTS AND AMOUNTS DECEMBER 31, COSTS AND AMOUNTS DECEMBER 31, COSTS AND
1992 EXPENSES WRITTEN OFF 1993 EXPENSES WRITTEN OFF 1994 EXPENSES
------------ --------- ----------- ------------ ----------- ----------- ------------ -----------
Allowance
for
uncollectible
accounts $(1,311,000 ) $(986,000) $1,154,000 $(1,143,000 ) $(1,101,000) $ 820,000 $(1,424,000 ) $(1,347,000)
BALANCE AT
AMOUNTS DECEMBER 31,
WRITTEN OFF 1995
----------- ------------
Allowance
for
uncollect
accounts $ 1,323,000 $(1,448,000 )
B-21
70
Consent of Independent Auditors
We consent to the incorporation by reference in the Registration Statement, as
amended, (Forms S-8 No. 2-90646; No. 33-21509; No. 33-48980) pertaining to the
1984 Stock Option Plan and Employment Agreement of American Shared Hospital
Services and in the Registration Statement (Form S-8, No. 33-45999) pertaining
to the American Shared Hospital Services 1991 Employee Stock Bonus Plan and in
the related Prospectuses of our report dated February 20, 1996, except for Note
16, as to which the date is March 8, 1996, with respect to the consolidated
financial statements and schedule of American Shared Hospital Services
included in the Annual Report (Form 10-K) for the year ended December 31, 1995.
ERNST & YOUNG LLP
Walnut Creek, California
March 29, 1996
C-1
71
INDEX TO EXHIBITS
Exhibit Sequential
Number Exhibit Description Page
- ------- ------------------- ----------
3.1 Articles of Incorporation of the
Company, as amended. (1) *
3.2 By-laws of the Company, as amended.(2) *
4.1 Indenture between American Shared Hospital
Services and First Interstate Bank of California, as
Trustee, dated October 15, 1988, relating to the
Senior Subordinated Exchangeable Reset Notes Due
1996. (1) *
4.2 Indenture between American Shared Hospital
Services and First Interstate Bank of California, as
Trustee, dated October 15, 1988, relating to the
14-3/4% Senior Subordinated Notes Due 1996. (1) *
- --------------------
* Not applicable
(1) These documents were filed as Exhibits 3.1, 4.1 and 4.2,
respectively, to registrant's Registration Statement on Form S-2
(Registration No. 33-23416), which is incorporated herein by this
reference.
(2) This document was previously filed as Exhibit 3.2 to registrant's
Registration Statement on Form S-1 (Registration No. 33-63721) filed
on October 26, 1995, which is incorporated herein by this reference.
72
4.3 Supplemental Indenture No. 1, dated as of
October 15, 1989, to the Indenture between American
Shared Hospital Services and First Interstate Bank
of California, as Trustee, dated October 15, 1988,
relating to the Senior Subordinated Exchangeable
Reset Notes Due 1996. (1) *
4.4 Supplemental Indenture No. 2, dated as of May 17,
1995 to the Indenture between American Shared
Hospital Services and First Interstate Bank of
California, as Trustee, dated October 15, 1988
relating to the Senior Subordinated Exchangeable
Reset Notes Due 1996. (2) *
4.5 Supplemental Indenture No. 1, dated as of May 17,
1995, to the Indenture between American Shared
Hospital Services and First Interstate Bank of
California, as Trustee, dated October 15, 1988,
relating to the 14-3/4% Senior Subordinated Notes
Due 1996.(2) *
4.6 Form of Common Stock Purchase Warrant held by
Selling Noteholders of American Shared Hospital
Services.(2) *
4.7 Common Stock Purchase Warrant for Shares of
Common Stock of American Shared Hospital Services
held by General Electric Company, acting through GE
Medical Systems. (2) *
- --------------------
* Not applicable
(1) This document was filed as Exhibit 4.3 to registrant's Annual Report
on Form 10-K for the year ended December 31, 1989, which is
incorporated herein by this reference.
(2) These documents were filed as Exhibits 4.4, 4.5, 4.6 and 4.7,
respectively, to registrant's Registration Statement on Form S-1
(Registration No. 33-63721) filed on October 26, 1995, which is
incorporated herein by this reference.
73
4.8 Registration Rights Agreement, dated as of
May 17, 1995, by and among American Shared Hospital
Services, the Holders referred to in the Note
Purchase Agreement, dated as of May 12, 1995 and
General Electric Company, acting through GE Medical
Systems. (1) *
4.9 Promissory Note, dated May 17, 1995, by American
Shared Hospital Services in favor of General
Electric Company in the principal sum of $1,500,000,
as amended. (1) *
4.10 Promissory Note, dated January 31, 1996, by
American Shared-CuraCare and CuraCare, Inc. in favor
of DVI Business Credit Receivables Corporation, in
the principal sum of $4,000,000. (2) *
4.11 Promissory Note, dated May 17, 1995, by
American Shared-CuraCare and CuraCare, Inc. in favor
of DVI Financial Services Inc. in the principal sum
of $2,500,000. (1) *
4.12 Security Agreement, dated as of May 17, 1995,
by and between American Shared Hospital Services and
General Electric Company, acting through GE Medical
Systems. (1) *
- --------------------
* Not applicable
(1) These documents were filed as Exhibits 4.8, 4.9, 4.11 and 4.12,
respectively, to registrant's Registration Statement
on Form S-1 (Registration No. 33-63721) filed on
October 26, 1995, which is incorporated herein by
this reference.
(2) This document was filed as Exhibit 4.10 to registrant's Pre-Effective
Amendment No. 1 to the Registration Statement on
Form S-1 (Registration No. 33-63721) filed on March
29, 1996, which is incorporated herein by this
reference.
74
4.13 Agreement and Proxy, dated as of May 12, 1995 by *
Ernest A. Bates, M.D. Accepted and Agreed to by
Anchor National Life Insurance Company, Sun Life
Insurance Company of America, SunAmerica Inc., AIF
II, L.P., Lion Advisors, L.P., Grace Brothers, Ltd.,
and Upchurch Living Trust U/A/D 12/14/90. (1)
4.14 Assignment and Assumption Agreement, dated as
of December 31, 1995, between American Shared
Hospital Services (assignor) and American Shared
Radiosurgery Services (assignee). (2) *
4.15 Assignment and Assumption Agreement, dated as
of December 31, 1995, between American Shared
Radiosurgery Services (assignor) and GK Financing,
LLC (assignee). (2) *
4.16 USC University Hospital Option Agreement,
dated February 3, 1996, among American Shared
Hospital Services, Ernest A. Bates, M.D. and GK
Financing, LLC. (2) *
4.17 Assignment and Assumption Agreement, dated as
of February 1, 1996, among Ernest A. Bates, M.D.
(assignor) and GK Financing, LLC (assignee). (2) *
4.18 Assignment and Assumption Agreement,effective
as of February 3, 1996, among Ernest A. Bates, M.D.
(assignor) and GK Financing, LLC (assignee). (2) *
--------------------
* Not applicable
(1) This document was filed as Exhibit 4.13 to registrant's Registration
Statement on Form S-1 (Registration No. 33-63721) filed on October
26, 1995,, which is incorporated herein by this reference.
(2) These documents were filed as Exhibit 4.14, 4.15, 4.16, 4.17 and
4.18, respectively, to registrant's Pre- Effective Amendment No. 1 to
the Registration Statement on Form S-1 (Registration No. 33-63721)
filed on March 29, 1996, which is incorporated herein by this
reference.
75
4.19 Promissory Note, dated January 1, 1995, by
American Shared-CuraCare in favor of General
Electric Company, acting through GE Medical Systems,
in the principal sum of $2,000,000, as amended. (1) *
4.20 Promissory Note, dated January 1, 1995, by
American Shared-CuraCare in favor of General
Electric Company, in the principal sum of
$481,667.81, as amended. (1) *
10.1 The Company's 1984 Stock Option Plan,
as amended. (2) *
10.2 The Company's 1995 Stock Option Plan.(3) *
10.3 Form of Indemnification Agreement between
American Shared Hospital Services and members of its
Board of Directors. (2) *
- --------------------
* Not applicable
(1) These documents were filed as Exhibits 4.19 and 4.20, respectively,
to the registrant's Pre-Effective Amendment No. 1 to the Registration
Statement on Form S-1 (Registration No. 33-63721) filed on March 29,
1996, which is incorporated herein by this reference.
(2) These documents were filed as Exhibits 10.24 and 10.35, respectively,
to registrant's Registration Statement on Form S-2 (Registration No.
33-23416), which is incorporated herein by this reference.
(3) This document was filed as Exhibit A to registrant's Proxy Statement
filed on August 31, 1995, which is incorporated herein by this
reference.
76
10.4 Agreement, effective as of November 1, 1994,
by and among General Electric Company, acting
through GE Medical Systems, and American Shared
Hospital Services, and certain of its subsidiaries.
(1) *
10.5 Note Purchase Agreement dated as of May 12, 1995,
by and among Anchor National Life Insurance Company,
Sun Life Insurance Company of America, and
SunAmerica Inc., AIF II, L.P., Lion Advisors, L.P.,
Grace Brothers, Ltd., Upchurch Living Trust U/A/D
12/14/90, American Shared Hospital Services and
Ernest A. Bates, M.D.(2) *
10.6 Loan and Security Agreement, dated as of May 17,
1995, among American Shared-Curacare and Curacare,
Inc., American Shared Hospital Services, Ernest A.
Bates, M.D. and DVI Business Credit Receivables
Corporation. (3) *
10.7 Loan and Security Agreement, dated as of May 17,
1995, among American Shared-CuraCare and CuraCare,
Inc., American Shared Hospital Services, Ernest A.
Bates, M.D. and DVI Financial Services Inc. (2) *
- --------------------
* Not applicable
(1) This document was filed as Exhibit 10.49 to registrant's Annual
Report on Form 10-K for the fiscal year ended December 31, 1994,
which is incorporated herein by this reference.
(2) These documents were filed as Exhibits 10.5 and 10.7, respectively,
to registrant's Registration Statement on Form S-1 (Registration No.
33-63721) filed on October 26, 1995, which is incorporated herein by
this reference.
(3) This document was filed as Exhibit 10.6 to registrant's Pre-Effective
Amendment No. 1 to the Registration Statement on Form S-1
(Registration No. 33-63721) filed on March 29, 1996, which is
incorporated herein by this reference.
77
10.8 Form of Unconditional Continuing Guaranty of
American Shared Hospital Services. (1) *
10.9 Form of Unconditional Continuing Guaranty
of Ernest A. Bates, M.D. (1) *
10.10 Intercreditor Agreement, dated as of May 17,
1995, among American Shared Hospital Services,
American Shared- CuraCare, DVI Financial Services
Inc. and DVI Business Credit Receivables Corporation
and General Electric Company, acting through GE
Medical Systems. (1) *
- --------------------
* Not applicable
(1) These documents were filed as Exhibits 10.8, 10.9 and 10.10,
respectively, to registrant's Pre-Effective Amendment No. 1 to the
Registration Statement on Form S-1 (Registration No. 33-63721) filed
on March 29, 1996, which is incorporated herein by this reference.
78
10.11 Ernest A. Bates Stock Option
Agreement, dated August 15, 1995. (1) *
10.12 Operating Agreement for GK Financing, LLC,
dated as of October 17, 1995.(2) *
10.13 Amendments dated as of October 26, 1995,
and as of December 20, 1995 to the GK Financing, LLC
Operating Agreement, dated as of October 17, 995.
(3) *
21 Subsidiaries of American Shared
Hospital Services. (3) *
23.1 Consent of Ernst & Young LLP.
- --------------------
* Not applicable
(1) This document was filed as Exhibit B to registrant's Proxy Statement
filed on August 31, 1995, which is incorporated herein by this
reference.
(2) This document was previously filed as Exhibit 10.12 to registrant's
Registration Statement on Form S-1 (Registration No. 33-63721) filed
on October 26, 1995, which is incorporated herein by this reference.
(3) These documents were filed as Exhibits 10.13 and 21, respectively, to
registrant's Pre-Effective Amendment No. 1 to the Registration
Statement on Form S-1 (Registration No. 33-63721) filed on March 29,
1996, which is incorporated herein by this reference.